

2023

AUSTRALIAN DIABETES CLINICAL QUALITY REGISTRY

SUPPLEMENT





CONTENTS

ABBREVIATIONS AND ACRONYMS	3
BACKGROUND	4
DATA QUERIES, ASSUMPTIONS AND MANIPULATIONS	5
STATISTICAL ANALYSES	7
KEY FINDINGS	8
FREQUENCY COUNT DATA	12
MISSING DATA	31
DESCRIPTIVE REPORT	36
POST DATA COLLECTON QUESTIONNAIRE RESULTS	123
REFERENCES	124
ADCQR COMMITTEES	125
APPENDICES	127

ABBREVIATIONS AND ACRONYMS

ADCQR Australian Diabetes Clinical Quality Registry ADS Australian Diabetes Society ANDA Australian National Diabetes Audit ARB Angiotensin II Receptor Blockers BMI Body Mass Index BP Blood Pressure CABG Coronary Artery Bypass Graft COVID-19 Coronavirus disease-2019 CSII Continuous Subcutaneous Insulin Infusion CQR Clinical Quality Registry DKA Diabetic Ketoacidosis DPP4 Dipeptidyl Peptidase-4 DVA Department of Veterans Affairs eGFR Estimated Glomerular Filtration Rate GIP Gastric Inhibitory Polypeptide GLP-1 Glucagon-Like Peptide-1 HbA1c Glycated Haemoglobin HDL High-Density Lipoprotein HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 SpHPM School of Public Health and Preventive Medicine	105	
ADS Australian Diabetes Society ANDA Australian National Diabetes Audit ARB Angiotensin II Receptor Blockers BMI Body Mass Index BP Blood Pressure CABG Coronary Artery Bypass Graft COVID-19 Coronavirus disease-2019 CSII Continuous Subcutaneous Insulin Infusion CGR Clinical Quality Registry DKA Diabetic Ketoacidosis DPP4 Dipeptidyl Peptidase-4 DVA Department of Veterans Affairs eGFR Estimated Glomerular Filtration Rate GIP Gastric Inhibitory Polypeptide GLP-1 Glucagon-Like Peptide-1 HbA1c Glycated Haemoglobin HDL High-Density Lipoprotein HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	ACE	Angiotensin Converting Enzyme
ANDA Australian National Diabetes Audit ARB Angiotensin II Receptor Blockers BMI Body Mass Index BP Blood Pressure CABG Coronary Artery Bypass Graft COVID-19 Coronavirus disease-2019 CSII Continuous Subcutaneous Insulin Infusion CQR Clinical Quality Registry DKA Diabetic Ketoacidosis DPP4 Dipeptidyl Peptidase-4 DVA Department of Veterans Affairs eGFR Estimated Glomerular Filtration Rate GIP Gastric Inhibitory Polypeptide GLP-1 Glucagon-Like Peptide-1 HbA1c Glycated Haemoglobin HDL High-Density Lipoprotein HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine		, , ,
ARB Angiotensin II Receptor Blockers BMI Body Mass Index BP Blood Pressure CABG Coronary Artery Bypass Graft COVID-19 Coronavirus disease-2019 CSII Continuous Subcutaneous Insulin Infusion CQR Clinical Quality Registry DKA Diabetic Ketoacidosis DPP4 Dipeptidyl Peptidase-4 DVA Department of Veterans Affairs eGFR Estimated Glomerular Filtration Rate GIP Gastric Inhibitory Polypeptide GLP-1 Glucagon-Like Peptide-1 HbA1c Glycated Haemoglobin HDL High-Density Lipoprotein HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine		<u> </u>
BMI Body Mass Index BP Blood Pressure CABG Coronary Artery Bypass Graft COVID-19 Coronavirus disease-2019 CSII Continuous Subcutaneous Insulin Infusion CQR Clinical Quality Registry DKA Diabetic Ketoacidosis DPP4 Dipeptidyl Peptidase-4 DVA Department of Veterans Affairs eGFR Estimated Glomerular Filtration Rate GIP Gastric Inhibitory Polypeptide GLP-1 Glucagon-Like Peptide-1 HbA1c Glycated Haemoglobin HDL High-Density Lipoprotein HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine		
BP Blood Pressure CABG Coronary Artery Bypass Graft COVID-19 Coronavirus disease-2019 CSII Continuous Subcutaneous Insulin Infusion CQR Clinical Quality Registry DKA Diabetic Ketoacidosis DPP4 Dipeptidyl Peptidase-4 DVA Department of Veterans Affairs eGFR Estimated Glomerular Filtration Rate GIP Gastric Inhibitory Polypeptide GLP-1 Glucagon-Like Peptide-1 HbA1c Glycated Haemoglobin HDL High-Density Lipoprotein HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	ARB	Angiotensin II Receptor Blockers
CABG Coronary Artery Bypass Graft COVID-19 Coronavirus disease-2019 CSII Continuous Subcutaneous Insulin Infusion CQR Clinical Quality Registry DKA Diabetic Ketoacidosis DPP4 Dipeptidyl Peptidase-4 DVA Department of Veterans Affairs eGFR Estimated Glomerular Filtration Rate GIP Gastric Inhibitory Polypeptide GLP-1 Glucagon-Like Peptide-1 HbA1c Glycated Haemoglobin HDL High-Density Lipoprotein HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	ВМІ	Body Mass Index
COVID-19 Coronavirus disease-2019 CSII Continuous Subcutaneous Insulin Infusion CQR Clinical Quality Registry DKA Diabetic Ketoacidosis DPP4 Dipeptidyl Peptidase-4 DVA Department of Veterans Affairs eGFR Estimated Glomerular Filtration Rate GIP Gastric Inhibitory Polypeptide GLP-1 Glucagon-Like Peptide-1 HbA1c Glycated Haemoglobin HDL High-Density Lipoprotein HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	BP	Blood Pressure
CSII Continuous Subcutaneous Insulin Infusion CQR Clinical Quality Registry DKA Diabetic Ketoacidosis DPP4 Dipeptidyl Peptidase-4 DVA Department of Veterans Affairs eGFR Estimated Glomerular Filtration Rate GIP Gastric Inhibitory Polypeptide GLP-1 Glucagon-Like Peptide-1 HbA1c Glycated Haemoglobin HDL High-Density Lipoprotein HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	CABG	Coronary Artery Bypass Graft
CQR Clinical Quality Registry DKA Diabetic Ketoacidosis DPP4 Dipeptidyl Peptidase-4 DVA Department of Veterans Affairs eGFR Estimated Glomerular Filtration Rate GIP Gastric Inhibitory Polypeptide GLP-1 Glucagon-Like Peptide-1 HbA1c Glycated Haemoglobin HDL High-Density Lipoprotein HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	COVID-19	Coronavirus disease-2019
DKA Diabetic Ketoacidosis DPP4 Dipeptidyl Peptidase-4 DVA Department of Veterans Affairs eGFR Estimated Glomerular Filtration Rate GIP Gastric Inhibitory Polypeptide GLP-1 Glucagon-Like Peptide-1 HbA1c Glycated Haemoglobin HDL High-Density Lipoprotein HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	CSII	Continuous Subcutaneous Insulin Infusion
DPP4 Dipeptidyl Peptidase-4 DVA Department of Veterans Affairs eGFR Estimated Glomerular Filtration Rate GIP Gastric Inhibitory Polypeptide GLP-1 Glucagon-Like Peptide-1 HbA1c Glycated Haemoglobin HDL High-Density Lipoprotein HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	CQR	Clinical Quality Registry
DVA Department of Veterans Affairs eGFR Estimated Glomerular Filtration Rate GIP Gastric Inhibitory Polypeptide GLP-1 Glucagon-Like Peptide-1 HbA1c Glycated Haemoglobin HDL High-Density Lipoprotein HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	DKA	Diabetic Ketoacidosis
eGFR Estimated Glomerular Filtration Rate GIP Gastric Inhibitory Polypeptide GLP-1 Glucagon-Like Peptide-1 HbA1c Glycated Haemoglobin HDL High-Density Lipoprotein HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	DPP4	Dipeptidyl Peptidase-4
GIP Gastric Inhibitory Polypeptide GLP-1 Glucagon-Like Peptide-1 HbA1c Glycated Haemoglobin HDL High-Density Lipoprotein HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	DVA	Department of Veterans Affairs
GLP-1 Glucagon-Like Peptide-1 HbA1c Glycated Haemoglobin HDL High-Density Lipoprotein HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	eGFR	Estimated Glomerular Filtration Rate
HbA1c Glycated Haemoglobin HDL High-Density Lipoprotein HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	GIP	Gastric Inhibitory Polypeptide
HDL High-Density Lipoprotein HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	GLP-1	Glucagon-Like Peptide-1
HHS Hyperosmolar Hyperglycaemic State IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	HbA1c	Glycated Haemoglobin
IQR Interquartile Range LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	HDL	High-Density Lipoprotein
LDL Low-Density Lipoprotein NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	HHS	Hyperosmolar Hyperglycaemic State
NADC National Association of Diabetes Centres NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	IQR	Interquartile Range
NDOQRIN National Diabetes Outcomes Quality Review Initiative NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	LDL	Low-Density Lipoprotein
NDSS National Diabetes Services Scheme Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	NADC	National Association of Diabetes Centres
Non-HDL Non-High-Density Lipoprotein PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	NDOQRIN	National Diabetes Outcomes Quality Review Initiative
PCR Protein-to-Creatinine Ratio PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	NDSS	National Diabetes Services Scheme
PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9 REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	Non-HDL	Non-High-Density Lipoprotein
REDCap Research Electronic Data Capture SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	PCR	Protein-to-Creatinine Ratio
SD Standard Deviation SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	PCSK9	Proprotein Convertase Subtilisin/Kexin Type 9
SGLT2 Sodium-Glucose Co-Transporter 2 SPHPM School of Public Health and Preventive Medicine	REDCap	Research Electronic Data Capture
SPHPM School of Public Health and Preventive Medicine	SD	Standard Deviation
	SGLT2	Sodium-Glucose Co-Transporter 2
TADM Type 1 Dishetes Mellitus	SPHPM	School of Public Health and Preventive Medicine
TIDM Type i Diabetes Meintus	T1DM	Type 1 Diabetes Mellitus
T2DM Type 2 Diabetes Mellitus	T2DM	Type 2 Diabetes Mellitus

BACKGROUND

This is the Supplement to the Australian Diabetes Clinical Quality Registry 2023 Annual Report.

The background and methodology are included in detail in the Annual Report.

In brief, the Australian Diabetes Clinical Quality Registry (ADCQR), successor to the Australian National Diabetes Audit (ANDA), is a clinician-led, Australian Government funded national clinical quality registry for adults with diabetes. It collects data from adults with diabetes attending health care services providing diabetes care across Australia. The data collected captures clinical (process, risk factor and outcome) indicators, as well as patient reported outcomes comprising of self-care/management and health service utilisation.

Most of the variables captured in the dataset have been collected using yes/no responses or other choice options to reduce the amount of written data required. The data collection forms and data definitions document, which was provided to participating health services (sites) to assist in the collection of data, are included in the Appendices at the end of this document.

Herein, we provide details on data queries, assumptions and manipulations, data analysis and results. More specifically, this Supplement provides detailed information on frequency counts and missingness of data for each variable, as well as descriptive reporting.

This Supplement also provides key findings highlighting the proportion of patients meeting guideline recommended clinical targets.

DATA QUERIES, ASSUMPTIONS AND MANIPULATIONS

Data queries were generated and queried with participating sites, including fields with missing data and/or potentially incorrect values. Possible participant (patient) duplicates (due to double individual registration/data entry) were queried based on: sex, date of birth, country of birth matches.

Data assumptions and decisions were made based on the following rules:

Missing data were calculated conditionally where relevant:

- Date of visit =01/06/2023 if missing
- Insulin = Yes, if insulin duration and/or mode indicated
- Day = 01 if day is missing in any of the date fields, but month and year are provided
- Month = 01 if month is missing in any of the date fields, but year is provided

Invalid data were excluded:

- Age <18 years
- Year of birth <1900
- Incorrect date formats (e.g. month >12)
- Date of birth after visit date
- Male = Pregnant or Female aged <18 or >55 = Pregnant
- T1DM and insulin use not indicated, unless <12 months since diagnosis
- T1DM and on insulin ≥3 years after date of diagnosis
- T1DM and sulphonylurea = Yes
- 'Year of diagnosis' and 'Insulin duration' excluded if < calculated age
- Calculated years of diagnosis < years on insulin > calculated age
- Number of finger pricks a day <1
- Proportion of time using sensors if continuous/flash glucose monitoring not indicated
- Height <1.3 metres or >2.2 metres
- Weight <40 kilograms or >200 kilograms
- Calculated BMI <15 kg/m² or >50 kg/m²
- Systolic BP < diastolic BP OR systolic or diastolic BP is missing
- Systolic BP <70mmHg or >200mmHg
- Diastolic BP <40mmHg or >130mmHg
- Urinary albumin/protein value, if units not indicated
- HbA1c <3%
- HbA1c >22%*
- Total cholesterol <2.0 mmol/L*
- HDL cholesterol >2.5 mmol/L*
- Triglyceride <0.5 mmol/L*
- Creatinine <50 or >1000 µmol/L*
- Congestive cardiac failure = Yes for both diagnosed/detected in the last 12 months and prior to the last 12 months*
- Dementia = Yes for both diagnosed/detected in the last 12 months and prior to the last 12 months*
- End stage kidney disease = Yes for both diagnosed/detected in the last 12 months and prior to the last 12 months*
- Retinopathy = No in the last 12 months, but treatment for retinopathy = Yes in the last 12 months*
- Retinopathy = No prior to the last 12 months, but treatment for retinopathy = Yes prior to the last 12 months*

^{*}Data gueried, but not excluded

Data manipulations and derivation applied to fields with invalid data:

- Age was calculated: Current year Year of birth. If visit date was unavailable, date was assumed to be 01/06 of the report year.
- Diagnosis date = Start of insulin date (if Start of insulin date was before Diagnosis date)
- Duration of diabetes was calculated: Current year Year of diagnosis
- Only unknown/missing diabetes type, were reclassified to T1DM using the following criteria:
 - If patient was on insulin therapy and pump (this applies for any age at diagnosis and any time from diagnosis to insulin therapy as long as there is no missing data)
 - If age at diagnosis <30 years and time from diagnosis to insulin therapy ≤1 year and patient was on insulin therapy
 - If age at diagnosis <30 years and time from diagnosis to insulin therapy (>1 and <3) years and patient is on insulin therapy and (basal bolus or pump)
- Only unknown/missing diabetes type, were reclassified to T2DM using the following criteria:
 - If age at diagnosis ≥30 years and time from diagnosis to insulin therapy ≥3 years and patient was on insulin therapy
- Finger pricking changed to 'Yes' if check as often as recommended, or number of times a day was indicated
- 'Diet only' changed to 'No' if other management methods details were indicated
- Self-monitoring of glucose = None changed to 'No' if any other monitoring methods were indicated
- Glycaemic management method for Insulin changed to 'Yes' if any of the insulin modes were selected
- Insulin mode = pump changed to 'Yes' if any of the pump types were indicated
- If hybrid closed loop system was indicated as 'Yes', CSII non-automated was changed to 'Yes'
- BMI was calculated: weight (kg)/height (m)². If height was greater than 2.5, it was assumed that it was reported in metres instead of centimetres.
- Instances where patients reported multiple modes of insulin, the following hierarchical algorithm was used: Hybrid closed loop system > Pump > Basal bolus > Pre-mixed > Basal
- Anti-hypertensive therapy changed to 'No' if no medications were indicated
- Anti-hypertensive therapy changed to 'Yes' if any medications were indicated
- 'Lipid modifying therapy' changed to 'No' if no therapy details were indicated
- 'Lipid modifying therapy' changed to 'Yes' if any therapy details were indicated (as 'Yes')
- Urinary protein/albumin assessment was used to define albuminuria based on published guidelines for laboratory thresholds
- Urinary albumin was the primary measure to define albuminuria and where urinary albumin was missing, urinary protein was used to define albuminuria
- Lipids measured changed to 'Yes' if any of the lipid measurements were provided
- Lipids measured changed to 'No' if no measurements were provided
- Lipid non-HDL cholesterol was calculated: Total cholesterol HDL cholesterol
- Lower limb amputation changed to 'Yes' if any of the minor or major amputation types were indicated as 'Yes'
- Severe hypoglycaemia changed to 'Yes' if 'No. of episodes' was indicated
- 'COVID-19' changed to 'Yes' if 'Hospitalisation required (for COVID-19)' was indicated as 'Yes'
- 'Current smoker' changed to 'No' if 'Previously smoked' was indicated as 'Yes'
- 'Forget medications' was changed to 'Yes' if number of times was indicated

STATISTICAL ANALYSES

Descriptive statistics

Results are presented descriptively as frequencies and percentages for categorical variables, and mean and standard deviation (SD) for continuous variables. Variables that were not normally distributed are presented as median and interquartile range (IQR, where IQR is represented by the first quartile (Q1 or 25th percentile) and third quartile (Q3 or 75th percentile)). Percentages may not always add to 100% due to rounding. In the tables, % was calculated using the denominator for the total cohort (including missing data) while Relative % was calculated assuming the denominator did not include missing data.

Missing Data

Missing data are reported as frequency and percentage. Percentage was calculated from the total number of applicable respondents (for example; missing pregnancy data is calculated from the total number of female patients of reproductive age).

Descriptive Reports

The descriptive reports provide a breakdown of data by diabetes type for patient characteristics and outcomes. Raw data are demonstrated in tabular or descriptive format, and the corresponding bar charts demonstrate the mean, median or percentage by participating site. In each table, R% reflects the percentage of patients by variable options, e.g. males versus females. Alternatively, C% reflects the percentage of patients in each variable by sub-group, e.g. diabetes type (T1DM, T2DM, other or don't know). In each bar chart, individual bars across the x-axis represent a single data collection site, and the y-axis corresponds to the mean, median or percentage at the individual site for that characteristic. The bars are presented in descending order, with the data from a site with the highest mean, median or percentage presented on the left. Note that there are variable numbers of bars across different charts - as data for certain characteristics were not recorded at every site. At the site level, the distribution of key clinical outcomes appeared normally distributed for the majority of outcomes and therefore the means are utilised in the descriptive reports. For HbA1c, duration of diabetes, triglycerides, urinary albumin and urinary protein. median and IQR values are utilised as the data were not normally distributed. Note that where low numbers were reported, descriptive reports were not presented. However, where descriptive reports are provided but patient numbers are on the lower side, please interpret with caution.

Complications were defined as: cerebral stroke, myocardial infarction, congestive cardiac failure, CABG/angioplasty, end stage renal disease, foot ulceration, foot amputation, retinopathy, blindness, sexual dysfunction, diabetic ketoacidosis, hyperosmolar hyperglycaemic state or severe hypoglycaemia. Cardiovascular possible complications include macrovascular/microvascular complications. Complications/comorbidities are reported as ever reported (percentage of patients with a diagnosis/detection either in the last 12 months or prior to the last 12 months).

KEY FINDINGS

DEMOGRAPHICS



25
Participating Centres



1426
Patients



14
Centres of Excellence & Tertiary Care

Centres



Secondary & Primary Care Centres



States & Territories

SEX DISTRIBUTION



45.0% Females




54.9% Males



0.1% Other

TYPES OF DIABETES*



*Excluding unknown or unstated diabetes type

MEAN AGE



T2DM **66.0** Years

MEDIAN DURATION OF DIABETES



T2DM 14.6 Years

BLOOD GLUCOSE MONITORING

T1DM BLOOD GLUCOSE MONITORING

17.6%

Blood Glucose Self Monitoring Only

77.1%

Continuous Glucose/Flash Monitoring Only

5.3%

Both Blood & Continuous Glucose/Flash Monitoring

T2DM BLOOD GLUCOSE MONITORING

78.5%

Blood Glucose Self Monitoring Only

5.2%

Continuous Glucose/Flash Monitoring Only

0.2%

Both Blood & Continuous Glucose/Flash Monitoring

NO REGULAR BLOOD GLUCOSE MONITORING



T1DM: Type 1 Diabetes Mellitus; T2DM: Type 2 Diabetes Mellitus

GLUCOSE MANAGEMENT

T1DM INSULIN REGIMENS



72.2%

Multiple Daily Injections



Continuous Subcutaneous Insulin Infusion



2.1% Additional Non-Insulin Therapy

GLUCOSE MANAGEMENT

MEAN HBA1C (%)

8.2%

8.0%

MEDIAN HBA1C (%)

7.8%

7.8%

PROPORTION OF PATIENTS WITH T2DM ON GLUCOSE LOWERING THERAPIES

43.1%

38.0%


On 1 Therapy

On 2 Therapies

18.9%

On ≥3 Therapies

TYPES OF GLUCOSE LOWERING THERAPIES (T2DM ONLY)



RISK FACTORS

CHOLESTEROL



45.3%

Total Cholesterol <4.0 mmol/L

66.8%

On Lipid Modifying Therapy

SMOKING



32.3%Past Smokers

12.2%

Current Smokers

BLOOD PRESSURE



31.2%

Blood Pressure <130/80 mmHg

64.9%

Blood Pressure <140/90 mmHg

66.1%

On Anti-Hypertensive Therapy

WEIGHT



31.1 KG/M²

Mean BM

T1DM 31.2%

Not Overweight/Obese

T2DM 13.2%

Not Overweight/Obese

COMPLICATIONS (EVER REPORTED)

FOOT COMPLICATIONS



9.4% Foot Ulceration

20.8% Peripheral Neuropathy

5.0% Amputation

KIDNEY AND EYE DISEASE



25.5% Retinopathy



6.0% End-Stage Kidney Disease

CARDIOVASCULAR DISEASE



16.2% Myocardial Infarction/CABG

7.0% Stroke




7.9%

Peripheral Vascular Disease

OVERALL COMPLICATIONS



EXPERIENCED SEVERE



EXPERIENCED DKA OR HHS*



*In the last 12 months

CABG: Coronary Artery Bypass Graft; DKA: Diabetic Ketoacidosis; HHS: Hyperosmolar Hyperglycaemic State

PATIENT REPORTED OUTCOMES

HEALTH PROFESSIONAL ATTENDANCES (IN THE LAST 12 MONTHS)



65.6%

Endocrinologist



82.2%

Ophthalmologist/Optometrist



66.2%

Diabetes Educator/Nurse Practitioner



12.0%

Psychologist/Psychiatrist



30.7%

Dietitian



58.4%

Podiatrist

PHYSICAL ACTIVITY



33.1%

≥150 Mins/Week Moderate Or Vigorous Activity

33.7%

Muscle Strengthening

Exercise





Sufficient Time To Prepare Healthy Meals



Know What Foods Are Best To Eat 64.0%

Not Too Costly To Eat Well



T1DM Only - Not Hard To Count Carbs/Weigh Food

VACCINATIONS



39.4%

Received A COVID-19 Vaccination/ Booster In The Last 6 Months



69.3%

Received An Influenza Vaccination In The Last 12 Months



24.8%

Were Up-To-Date With Pneumococcal Vaccination

FREQUENCY COUNT DATA

SECTION 1. PATIENT DEMOGRAPHICS

			SECTION 1. PATI	ENT DEMO	GRAPHICS					
Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
1.0	Consu	Itation method								
		In person	1217	85.3%	85.7%					
		Phone	56	3.9%	3.9%					
		Video	147	10.3%	10.4%					
		Missing	6	0.4%		_				
		Sum	1426	100%	100%					
1.1	Date of	f birth								
		DOB	1425	99.9%	100%					
		Missing	1	0.1%		_				
		Sum	1426	100%	100%					
	Age									
		Age (years)	1425	99.9%	100%	63.9	60.2	17.1	18.0	99.5
		Missing	1	0.1%		_				
		Sum	1426	100%	100%	_				
1.2	Sex									
		Male	784	55.0%	55.0%					
		Female	641	45.0%	45.0%					
		Other	1	0.1%	0.2%					
		Missing	0	0.0%						
		Sum	1426	100%	100%	_				
1.2.1	Curren	itly pregnant (females aged 18-	-55 years)							
		Yes	14	6.2%	6.2%					
		No	211	93.0%	93.8%					
		Missing	2	0.9%						
		Sum	227	100%	100%					
1.3	Date of	f visit								
		Visit Date	1426	100.0%	100%					
		Missing	0	0.0%						
		Sum	1426	100%	100%					
1.4	NDSS	registrant								
		Yes	1335	93.6%	94.5%					
		No	78	5.5%	5.5%					
		Missing	13	0.9%						
		Sum	1426	100%	100%					
1.5	Aborig	inal/Torres Strait Islander								
		Yes	45	3.2%	3.2%					
		No	1380	96.8%	96.8%					
		Missing	1	0.1%						
		Sum	1426	100%	100%	-				
1.6	Initial v	visit								
		Yes	143	10.0%	10.1%					
		No	1278	89.6%	89.9%					
		Missing	5	0.4%						
		Sum	1426	100%	100%	-				

SECTION 1. PATIENT DEMOGRAPHICS (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
1.7	Interpr	eter required								
		Yes	72	5.0%	5.0%					
		No	1354	95.0%	95.0%					
		Missing	0	0.0%		_				
		Sum	1426	100%	100%					
1.8	Main la	inguage spoken at home								
		Language provided	1420	99.6%	100%					
		Missing	6	0.4%		_				
		Sum	1426	100%	100%	_				
1.9	DVA									
		Yes	9	0.6%	0.6%					
		No	1412	99.0%	99.4%					
		Missing	5	0.4%		_				
		Sum	1426	100%	100%	_				
1.10	Countr	y of birth								
		Country	1419	99.5%	100%					
		Missing	7	0.5%		_				
		Sum	1426	100%	100%	_				
1.11	Reside	ntial postcode								
		Postcode provided	1419	99.5%	100%					
		Missing	7	0.5%		_				
		Sum	1426	100%	100%	_				

SECTION 3	DIVELLE	TVDE 2	MANAGEMENT

		SECTION	2. DIABET	ES TYPE & N	MANAGEMENT					
Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
2.1	Date of	diagnosis								
		Year	1416	99.3%	100%					
		Missing	10	0.7%						
		Sum	1426	100%	100%	•				
	Diabete	es duration				Median	IQ	R	Min	Max
		Diabetes duration (years)	1416	99.3%	100%	15.5	8.0 - 2	23.7	0.0	73.5
		Missing	10	0.7%						
		Sum	1426	100%	100%					
2.2	Type of	f diabetes								
	• •	T1DM	397	27.8%	27.8%					
		T2DM	988	69.3%	69.3%					
		Other	38	2.7%	2.7%					
		Don't know	3	0.2%	0.2%					
		Missing	0	0.0%						
		Sum	1426	100%	100%	-				
2.3	Self-mo	onitoring of glucose								
		None	162	11.4%	11.4%					
		Finger pricking only	875	61.4%	61.4%					
		Continuous glucose monitoring only	363	25.5%	25.5%					
		Finger pricking and CGM	24	1.7%	1.7%					
		Missing	2	0.1%						
		Sum	1426	100%	100%	•				
2.3.1	Check	as often as recommended**								
		Yes	629	70.0%	70.4%					
		No	231	25.7%	25.8%					
		Unsure	34	3.8%	3.8%					
		Missing	5	0.6%						
		Sum	899	100%	100%	-				
	**Of pati	ents using finger pricking								
2.3.2		r of times a day**				Median	Mean	SD	Min	Max
		Provided	869	96.7%	100.0%	2.0	2.2	1.3	0.0	10.0
		Missing	30	3.3%	.00.070				0.0	
		Sum	899	100%	100%					
	**Of pati	ents using finger pricking								
2.3.3		worn for ≥14 days in the last 3 month	ıc†							
2.3.3	0611301	Yes	352	91.0%	91.2%					
		No	34	8.8%	8.8%					
		Missing	1	0.3%	0.0 /0					
		Sum	387	100%	100%	-				
	† 06			100 /0	100 /0					
		ents using flash/continuous glucose monitorin	7							
2.3.4	Percen	tage of active time sensor [†]								
		<70%	55	91.0%	15.9%					
		≥70%	291	8.8%	84.1%					
		Missing	41	0.3%						
		Sum	387	100%	100%					
	t									

[†] Of patients using flash/continuous glucose monitoring

SECTION 2. DIABETES TYPE & MANAGEMENT (continued)

		2. DIABETES TYP	PE & MANA		nued)				
Item	Field Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
2.4	Management method								
	Diet only	41	2.9%	2.9%					
	Metformin**	791	55.5%	55.5%					
	Sulphonylurea**	236	16.5%	16.6%					
	Thiazolidinedione**	2	0.1%	0.1%					
	Acarbose**	13	0.9%	0.9%					
	DPP4 inhibitor**	254	17.8%	17.8%					
	SGLT2 inhibitor**	409	28.7%	28.7%					
	GLP1/GIP agonist**	352	24.7%	24.7%					
	Insulin**	986	69.1%	69.2%					
	Missing	2	0.1%						
0.4.4	**Monotherapy or in combination with other tre	atments							
2.4.1	Insulin duration**	07.4	07.00/	00.00/					
	<5 years	274	27.8%	28.6%					
	5-10 years	224	22.7%	23.4%					
	>10 years	461 27	46.8%	48.1%					
	Missing Sum	986	2.7% 100%	100%	-				
	**Of patients using insulin	900	100%	100%					
2.4.2	Insulin mode**								
L.7.L	Basal [†]	120	8.4%	8.4%					
	Basal bolus [†]	430	30.2%	30.2%					
	Pre-mixed insulin [†]	359	25.2%	25.2%					
	Pump [†]	111	7.8%	7.8%					
	Missing	2	0.1%						
	**Of patients using insulin								
	[†] Multiple modes of insulin reported in some pa	tients							
	Insulin mode: Pump**								
	CSII automated (Hybrid closed								
	loop system)	67	60.4%	60.9%					
	CSII automated (other)	16	14.4%	14.5%					
	CSII non-automated	27	24.3%	24.5%					
	Gon non-automateu		_ 1.0 /0						
	Missing	1	0.9%						

^{**}Of patients using insulin and pump

SECTION 3	WILLIAM	O LIFICIIT
SECTION:	VV FILSH I	~ HFI(1H I

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
3.1	Weight									
		Weight (kg)	1390	97.5%	100%	86.1	88.7	23.2	36.9	255.0
		Missing	36	2.5%		_				
		Sum	1426	100%	100%					
3.2	Height									
		Height (m)	1354	95.0%	100%	1.7	1.7	0.1	1.3	2.1
		Missing	72	5.0%		_				
		Sum	1426	100%	100%	_				

SECTION 4 BLOOD PRESSURE

		SECTION 4. B	LOOD PRE	SSURE					
Item	Field Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
4.1a	Systolic blood pressure								
	Systolic (mmHg)	1316	92.3%	100%	130	132	18	90	211
	Missing	110	7.7%		_				
	Sum	1426	100%	100%					
4.1b	Diastolic blood pressure								
	Diastolic (mmHg)	1316	92.3%	100%	78	77	11	34	115
	Missing	110	7.7%						
	Sum	1426	100%	100%					
4.1.1	Blood pressure method**								
	Measured in clinic	1125	85.5%	88.8%					
	Self-reported	142	10.8%	11.2%					
	Missing	49	3.7%		_				
	Sum	1316	100%	100%					
	**Of patients with blood pressure measured								
4.2	Anti-hypertensive therapy								
	Yes	943	66.1%	66.1%					
	No	483	33.9%	33.9%					
	Missing	0	0.0%		-				
	Sum	1426	100%	100%					
4.2.1	Anti-hypertensive therapies**								
	ACE inhibitor [†]	371	26.0%	26.0%					
	Thiazides/Diuretics [†]	247	17.3%	17.3%					
	Calcium channel blocker [†]	324	22.7%	22.7%					
	Beta blocker [†]	294	20.6%	20.6%					
	ARB^\dagger	425	29.8%	29.8%					
	Other anti-hypertensive [†]	94	6.6%	6.6%					
	Missing	0	0.0%						
	The state of the s								

^{**}Of patients on anti-hypertensive therapy

 $^{^{\}dagger}$ Monotherapy or in combination with other anti-hypertensive therapies

SECTION 5. BLOOD GLUCOSE CONTROL & RENAL FUNCTION

		SECTION 5. B	LOOD GLUCOS	E CONTRO	L & RENAL FU	NCTION				
Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
5.1	HbA _{1c}	result (%)								
		HbA _{1c} (%)	1381	96.8%	100%	7.8	8.1	1.7	4.4	16.3
		Missing	45	3.2%						
		Sum	1426	100%	100%	_				
5.1.1	HbA _{1c}	(%) test date								
		HbA _{1c} (%) test date provided	1381	96.8%	100%					
		Missing	45	3.2%						
		Sum	1426	100%	100%	_				
5.2	eGFR									
		eGFR (mL/min per 1.73m ²)	958	67.2%	100%	70.0	65.9	21.6	3.0	114.0
		Missing	468	32.8%						
		Sum	1426	100%	100%	_				
5.3	Serum	creatinine								
		Creatinine (µmol/L)	1308	91.7%	100%	80.0	97.6	86.7	33.0	1235.0
		Missing	118	8.3%		_				
		Sum	1426	100%	100%					
5.4a	Urinary	y albumin result (all units)								
		Result	919	64.4%	100%					
		Missing	507	35.6%		_				
		Sum	1426	100%	100%		10	_		
	Urinary	/ albumin result (mg/L)	005	40.00/	4000/	Median	IQ		Min	Max
	A !!	Result provided	265	18.6%	100%	14.4	5.0 -	60.0	0.0	4500.0
	Album	in:creatinine (ratio)	654	45.9%	100%	4.0	0.9 -	0.0	0.0	649.9
5.4b	Heiman	Result provided	004	45.9%	100%	1.9	0.9 -	· 6.U	0.0	049.9
J.4D	Urinary	y protein result (all units) Result provided	149	10.4%	100%					
		Missing	1277	89.6%	100%					
		Sum	1426	100%	100%	-				
	Urinan	y protein result (mg/L)	1420	100 /0	100 /0					
	Ullilar	Result provided	50	3.5%	100%	5.5	0.2 -	125.8	0.1	2580.0
	Proteir	n:creatinine (ratio)	30	0.070	100 /0	0.0	0.2 -	120.0	0.1	2000.0
	i ioteli	Result provided	99	6.9%	100%	4.5	0.7 -	18.6	0.0	1609.5
		1 toodit providod	00	0.070	10070	1.0	0.1	. 5.0	0.0	1000.0

SECTION 6. MEDICATIONS & LIPIDS

			SECTION 6. ME	DICATIONS	& LIPIDS					
Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
6.1	Aspirin									
	•	Yes	396	27.8%	27.8%					
		No	1020	71.5%	71.7%					
		Contraindicated	7	0.5%	0.5%					
		Missing	3	0.2%						
		Sum	1426	100%	100%	-				
6.2	Other a	nti-platelets		10070	10070					
U. <u>L</u>	Other u	Yes	95	6.7%	6.7%					
		No	1322	92.7%	92.9%					
		Contraindicated	6	0.4%	0.4%					
		Missing	3	0.4%	0.470					
					4000/	-				
C 2	A4!	Sum	1426	100%	100%					
6.3	Anti-co	agulants	407	0.00/	0.00/					
		Yes	137	9.6%	9.6%					
		No	1282	89.9%	90.1%					
		Contraindicated	4	0.3%	0.3%					
		Missing	3	0.2%		_				
		Sum	1426	100%	100%					
6.4	Lipid m	odifying therapy								
		Yes	951	66.7%	66.8%					
		No	472	33.1%	33.2%					
		Missing	3	0.2%						
		Sum	1426	100%	100%					
6.4.1	Statin**									
		Yes	893	93.9%	93.9%					
		No	47	4.9%	4.9%					
		Contraindicated	11	1.2%	1.2%					
		Missing	0	0.0%						
		Sum	951	100%	100%	-				
6.4.2	Fibrate ²									
		Yes	104	10.9%	11.0%					
		No	839	88.2%	88.7%					
		Contraindicated	3	0.3%	0.3%					
		Missing	5	0.5%	0.070					
		Sum	951	100%	100%	-				
6.4.3	Ezetimi		001	10070	10070					
0.4.0	LZCUIIII	Yes	133	14.0%	14.0%					
		No	811	85.3%	85.6%					
		Contraindicated	_	0.3%	0.3%					
		Missing	3 4	0.3%	0.570					
			951	100%	100%	-				
6 4 4	Fish oil	Sum **	901	100%	100%					
6.4.4	FISH OIL		400	14.00/	14.00/					
		Yes	133	14.0%	14.0%					
		No October 15 october 1	811	85.3%	85.6%					
		Contraindicated	3	0.3%	0.3%					
		Missing	4	0.4%		_				
		Sum	951	100%	100%					
6.4.5	PCSK9 [*]									
		Yes	4	0.4%	0.4%					
		No	941	98.9%	99.4%					
		Contraindicated	2	0.2%	0.2%					
		Missing	4	0.4%						
		iviissiriy		0.470		_				

^{**}Of patients on lipid modifying therapy

SECTION 6. MEDICATIONS & LIPIDS (continued)

		OLUI	ION O. MILDIOAI	IOITO & LII	ibo (continuca)					
Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
6.5	Lipids	measured								
		Yes	1078	75.6%	75.6%					
		No	348	24.4%	24.4%					
		Missing	0	0.0%						
		Sum	1426	100%	100%	_				
6.5.1	Total c	holesterol**								
		Total cholesterol (mmol/L)	1074	99.6%	100%	4.1	4.2	1.1	1.7	10.2
		Missing	4	0.4%		_				
		Sum	1078	100%	100%	_				
6.5.2	LDL**									
		LDL (mmol/L)	960	89.1%	100%	2.0	2.1	0.9	0.0	7.0
		Missing	118	10.9%		_				
		Sum	1078	100%	100%	_				
6.5.3	HDL**									
		HDL (mmol/L)	979	90.8%	100%	1.2	1.3	0.4	0.5	3.8
		Missing	99	9.2%		_				
		Sum	1078	100%	100%	_				
6.5.4	Triglyo	erides**				Median	IQ	R	Min	Max
		Triglycerides (mmol/L)	1067	99.0%	100%	1.5	1.0 -	2.1	0.3	24.4
		Missing	11	1.0%		_				
		Sum	1078	100%	100%	_				

^{**}Of patients with lipids measured

SECTION 7. DIABETES RELATED EYE & FOOT COMPLICATIONS

	SECTION 7. DIABI								
Item	Field Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
7.1a	Retinopathy - last 12 months								
	Yes	139	9.7%	9.8%					
	No	1283	90.0%	90.2%					
	Missing	4	0.3%						
	Sum	1426	100%	100%	_				
'.1b	Retinopathy - previous	1420	100 /0	100 /0					
.10		240	00.00/	00.40/					
	Yes	318	22.3%	22.4%					
	No	1104	77.4%	77.6%					
	Missing	4	0.3%		_				
	Sum	1426	100%	100%					
'.2a	Treatment for retinopathy - last 12 months								
	Yes	85	6.0%	6.0%					
	No	1338	93.8%	94.0%					
	Missing	3	0.2%	0 1.0 70					
	Sum	1426	100%	100%	_				
O.L.		1420	10076	10076					
'.2b	Treatment for retinopathy - previous	400	40.00/	40.40/					
	Yes	190	13.3%	13.4%					
	No	1233	86.5%	86.6%					
	Missing	3	0.2%		_				
	Sum	1426	100%	100%	_				
.3a	Right or left cataract - last 12 months								
	Yes	115	8.1%	8.1%					
	No	1309	91.8%	91.9%					
	Missing	2	0.1%	31.370					
	<u> </u>			4000/	_				
01	Sum	1426	100%	100%					
.3b	Right or left cataract - previous	000	20.40/	22 =2/					
	Yes	320	22.4%	22.5%					
	No	1104	77.4%	77.5%					
	Missing	2	0.1%		_				
	Sum	1426	100%	100%					
.4a	Blindness - last 12 months								
	Yes	13	0.9%	0.9%					
	No	1411	98.9%	99.1%					
	Missing	2	0.1%						
	Sum	1426	100%	100%	_				
.4b	Blindness - previous	0	10070	10070					
.76	Yes	28	2.0%	2.0%					
	No •••	1395	97.8%	98.0%					
	Missing	3	0.2%		_				
	Sum	1426	100%	100%					
.5a	Peripheral neuropathy - last 12 months								
	Yes	201	14.1%	14.1%					
	No	1223	85.8%	85.9%					
	Missing	2	0.1%						
	Sum	1426	100%	100%	_				
.5b	Peripheral neuropathy - previous		. 50,0	. 30 /0					
.00	Yes	237	16.6%	16.6%					
	No	1187	83.2%	83.4%					
				03.4%					
	Missing	2	0.1%	46601	_				
	Sum	1426	100%	100%					
.6a	Foot ulceration - last 12 months								
	Yes	92	6.5%	6.5%					
	No	1332	93.4%	93.5%					
	Missing	2	0.1%						
	Sum	1426	100%	100%	_				
.6b	Foot ulceration - previous	1-72-0	100/0	100/0					
.00	Yes	102	7.2%	7.2%					
	No		92.7%						
		1322		92.8%					
	Missing	2	0.1%	4000/	_				
	Sum	1426	100%	100%					

SECTION 7. DIABETES RELATED EYE & FOOT COMPLICATIONS (continued)

	SECTION 7. DIABETES	KELATED E	YE & F001	COMPLICATION	is (contin	uea)			
Item	Field Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
7.7a	Lower limb amputation - last 12 months								
	Yes	31	2.2%	2.2%					
	No	1393	97.7%	97.8%					
	Missing	2	0.1%						
	Sum	1426	100%	100%	-				
7.7.1a	Minor lower limb amputation - last 12 month	ıs							
	Yes	21	67.7%	67.7%					
	No	10	32.3%	32.3%					
	Missing	0	0.0%						
	Sum	31	100%	100%	-				
7.7.1b	Major lower limb amputation - last 12 month	s							
	Yes	9	29.0%	29.0%					
	No	22	71.0%	71.0%					
	Missing	0	0.0%						
	Sum	31	100%	100%	-				
7.7b	Lower limb amputation - previous								
	Yes	52	3.6%	3.7%					
	No	1372	96.2%	96.3%					
	Missing	2	0.1%		_				
	Sum	1426	100%	100%	-				
7.7.2a	Minor lower limb amputation - previous								
	Yes	38	73.1%	73.1%					
	No	14	26.9%	26.9%					
	Missing	0	0.0%						
	Sum	52	100%	100%	-				
7.7.2b	Major lower limb amputation - previous								
	Yes	6	11.5%	50.0%					
	No	6	11.5%	50.0%					
	Missing	40	76.9%						
	Sum	52	100%	100%	-				

SECTION 8. OTHER COMPLICATIONS/EVENTS/COMORBIDITIES

	SECTION 8. OTHER	COMPLIC	CATIONS/EV	'ENTS/COMORE	BIDITIES				
Item	Field Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
8.1a	Stroke - last 12 months								
	Yes	26	1.8%	1.8%					
	No	1398	98.0%	98.2%					
	Missing	2	0.1%						
	Sum	1426	100%	100%	-				
8.1b	Stroke - previous								
0.12	Yes	80	5.6%	5.6%					
	No	1342	94.1%	94.4%					
	Missing	4	0.3%	JT.T /0					
	Sum	1426	100%	100%	-				
8.2a	Myocardial infarction - last 12 months	1420	100 /0	100 /0					
0.Zd	•	40	2.8%	2.8%					
	Yes								
	No	1384	97.1%	97.2%					
	Missing	2	0.1%	4000/	-				
	Sum	1426	100%	100%					
8.2b	Myocardial infarction - previous								
	Yes	146	10.2%	10.3%					
	No	1277	89.6%	89.7%					
	Missing	3	0.2%		_				
	Sum	1426	100%	100%					
8.3a	CABG/Angioplasty - last 12 months								
	Yes	35	2.5%	2.5%					
	No	1389	97.4%	97.5%					
	Missing	2	0.1%						
	Sum	1426	100%	100%					
8.3b	CABG/Angioplasty - previous								
	Yes	153	10.7%	10.7%					
	No	1271	89.1%	89.3%					
	Missing	2	0.1%						
	Sum	1426	100%	100%	-				
8.4a	Congestive cardiac failure - last 12 months								
	Yes	15	1.1%	1.1%					
	No	1409	98.8%	98.9%					
	Missing	2	0.1%						
	Sum	1426	100%	100%	-				
8.4b	Congestive cardiac failure - previous								
VI 10	Yes	69	4.8%	4.8%					
	No	1355	95.0%	95.2%					
	Missing	2	0.1%	00.270					
	Sum	1426	100%	100%	-				
8.5a	Peripheral vascular disease - last 12 months	1720	100/0	100/0					
J.Ja	Yes	56	3.9%	3.9%					
	No	1368	5.9% 95.9%	96.1%					
				30.176					
	Missing	2	0.1%	4000/	-				
0 EL	Sum	1426	100%	100%					
8.5b	Peripheral vascular disease - previous	00	0.50/	0.50/					
	Yes	92	6.5%	6.5%					
	No	1332	93.4%	93.5%					
	Missing	2	0.1%		_				
	Sum	1426	100%	100%					
8.6a	End stage kidney disease - last 12 months								
	Yes	12	0.8%	0.8%					
	No	1412	99.0%	99.2%					
	Missing	2	0.1%		_				
	Sum	1426	100%	100%	_				
8.6b	End stage kidney disease - previous								
	Yes	73	5.1%	5.1%					
	No	1351	94.7%	94.9%					
	Missing	2	0.1%						
	Sum	1426	100%	100%	-				
									

	SECTION 8. OTHER C	OMPLICATION						
Item	Field Category	Total	%	Relative %*	Median	SD	Min	Max
8.7a	Sexual dysfunction - last 12 months							
	Yes	149	10.4%	10.6%				
	No	1259	88.3%	89.4%				
	Missing	18	1.3%					
	Sum	1426	100%	100%	-			
8.7b	Sexual dysfunction - previous							
011.0	Yes	149	10.4%	10.6%				
	No	1259	88.3%	89.4%				
	Missing	18	1.3%	03.4 /0				
	Sum	1426	100%	100%	-			
8.8a	Dementia - last 12 months	1420	100 /0	100 /0				
0.0a		5	0.4%	0.4%				
	Yes	1418						
	No Minimum		99.4%	99.6%				
	Missing	3	0.2%	4000/	-			
	Sum	1426	100%	100%				
8.8b	Dementia - previous							
	Yes	14	1.0%	1.0%				
	No	1410	98.9%	99.0%				
	Missing	2	0.1%		_			
	Sum	1426	100%	100%				
8.9a	Depression - last 12 months							
	Yes	182	12.8%	12.8%				
	No	1241	87.0%	87.2%				
	Missing	3	0.2%					
	Sum	1426	100%	100%	_			
8.9b	Depression - previous							
	Yes	315	22.1%	22.1%				
	No	1108	77.7%	77.9%				
	Missing	3	0.2%					
	Sum	1426	100%	100%	-			
8.10a	Anxiety - last 12 months							
	and the second s							
	Yes	168	11.8%	11.8%				
	Yes No	168 1256	11.8% 88.1%	11.8% 88.2%				
	No	1256	88.1%	11.8% 88.2%				
	No Missing	1256 2	88.1% 0.1%	88.2%				
	No Missing Sum	1256	88.1%		-			
8.10b	No Missing Sum Anxiety - previous	1256 2 1426	88.1% 0.1% 100%	88.2% 100%	-			
	No Missing Sum Anxiety - previous Yes	1256 2 1426 232	88.1% 0.1% 100% 16.3%	88.2% 100% 16.3%	-			
	No Missing Sum Anxiety - previous Yes No	1256 2 1426 232 1191	88.1% 0.1% 100% 16.3% 83.5%	88.2% 100%	-			
	No Missing Sum Anxiety - previous Yes No Missing	1256 2 1426 232 1191 3	88.1% 0.1% 100% 16.3% 83.5% 0.2%	100% 16.3% 83.7%	-			
8.10b	No Missing Sum Anxiety - previous Yes No Missing Sum	1256 2 1426 232 1191	88.1% 0.1% 100% 16.3% 83.5%	88.2% 100% 16.3%	-			
8.10b	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months	1256 2 1426 232 1191 3 1426	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100%	88.2% 100% 16.3% 83.7% 100%	-			
8.10b	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes	1256 2 1426 232 1191 3 1426	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100%	88.2% 100% 16.3% 83.7% 100% 2.4%	-			
8.10b	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes No	1256 2 1426 232 1191 3 1426	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100% 2.4% 97.5%	88.2% 100% 16.3% 83.7% 100%	-			
8.10b	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes No Missing	1256 2 1426 232 1191 3 1426 34 1390 2	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100% 2.4% 97.5% 0.1%	88.2% 100% 16.3% 83.7% 100% 2.4% 97.6%	-			
8.10b 8.11a	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes No Missing Sum Massing Sum Massing Sum Massing Sum	1256 2 1426 232 1191 3 1426	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100% 2.4% 97.5%	88.2% 100% 16.3% 83.7% 100% 2.4%	-			
	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes No Missing Sum Malignancy - previous	1256 2 1426 232 1191 3 1426 34 1390 2	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100% 2.4% 97.5% 0.1% 100%	88.2% 100% 16.3% 83.7% 100% 2.4% 97.6%	-			
8.10b 8.11a	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes No Missing Sum Malignancy - previous Yes Malignancy - previous Yes	1256 2 1426 232 1191 3 1426 34 1390 2 1426	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100% 2.4% 97.5% 0.1% 100%	88.2% 100% 16.3% 83.7% 100% 2.4% 97.6% 100% 7.7%	-			
8.10b 8.11a	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes No Missing Sum Malignancy - previous Yes No Missing Sum Malignancy - previous Yes No	1256 2 1426 232 1191 3 1426 34 1390 2 1426	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100% 2.4% 97.5% 0.1% 100% 7.7% 92.1%	88.2% 100% 16.3% 83.7% 100% 2.4% 97.6%	-			
8.10b 8.11a	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes No Missing Sum Malignancy - previous Yes No Missing Sum Malignancy - previous Yes No Missing Malignancy - previous Yes No Missing	1256 2 1426 232 1191 3 1426 34 1390 2 1426	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100% 2.4% 97.5% 0.1% 100% 7.7% 92.1% 0.2%	88.2% 100% 16.3% 83.7% 100% 2.4% 97.6% 100% 7.7% 92.3%	-			
8.10b 8.11a 8.11b	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes No Missing Sum Malignancy - previous	1256 2 1426 232 1191 3 1426 34 1390 2 1426	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100% 2.4% 97.5% 0.1% 100% 7.7% 92.1%	88.2% 100% 16.3% 83.7% 100% 2.4% 97.6% 100% 7.7%	-			
8.10b 8.11a	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes No Missing Sum Malignancy - previous Yes No Missing Sum Malignancy - previous Yes No Missing Sum Diabetic ketoacidosis - last 12 months	1256 2 1426 232 1191 3 1426 34 1390 2 1426 110 1313 3 1426	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100% 2.4% 97.5% 0.1% 100% 7.7% 92.1% 0.2% 100%	88.2% 100% 16.3% 83.7% 100% 2.4% 97.6% 100% 7.7% 92.3% 100%	-			
8.10b 8.11a 8.11b	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes No Missing Sum Malignancy - previous Yes No Missing Sum Malignancy - previous Yes No Missing Sum Diabetic ketoacidosis - last 12 months Yes	1256 2 1426 232 1191 3 1426 34 1390 2 1426 110 1313 3 1426	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100% 2.4% 97.5% 0.1% 100% 7.7% 92.1% 0.2% 100%	88.2% 100% 16.3% 83.7% 100% 2.4% 97.6% 100% 7.7% 92.3% 100% 2.0%	-			
8.10b 8.11a 8.11b	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes No Missing Sum Malignancy - previous Yes No Missing Sum Malignancy - previous Yes No Missing Sum Diabetic ketoacidosis - last 12 months	1256 2 1426 232 1191 3 1426 34 1390 2 1426 110 1313 3 1426	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100% 2.4% 97.5% 0.1% 100% 7.7% 92.1% 0.2% 100% 2.0% 97.9%	88.2% 100% 16.3% 83.7% 100% 2.4% 97.6% 100% 7.7% 92.3% 100%	-			
8.10b 8.11a 8.11b	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes No Missing Sum Malignancy - previous Yes No Missing Sum Malignancy - previous Yes No Missing Sum Diabetic ketoacidosis - last 12 months Yes	1256 2 1426 232 1191 3 1426 34 1390 2 1426 110 1313 3 1426	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100% 2.4% 97.5% 0.1% 100% 7.7% 92.1% 0.2% 100%	88.2% 100% 16.3% 83.7% 100% 2.4% 97.6% 100% 7.7% 92.3% 100% 2.0%	-			
8.10b 8.11a 8.11b	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes No Missing Sum Malignancy - previous Yes No Missing Sum Malignancy - previous Yes No Missing Sum Diabetic ketoacidosis - last 12 months Yes No	1256 2 1426 232 1191 3 1426 34 1390 2 1426 110 1313 3 1426	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100% 2.4% 97.5% 0.1% 100% 7.7% 92.1% 0.2% 100% 2.0% 97.9%	88.2% 100% 16.3% 83.7% 100% 2.4% 97.6% 100% 7.7% 92.3% 100% 2.0%				
8.10b 8.11a 8.11b	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes No Missing Sum Malignancy - previous Yes No Missing Sum Malignancy - previous Yes No Missing Sum Diabetic ketoacidosis - last 12 months Yes No Missing Sum Diabetic ketoacidosis - last 12 months Yes No Missing	1256 2 1426 232 1191 3 1426 34 1390 2 1426 110 1313 3 1426	88.1% 0.19 100% 16.3% 83.5% 0.2% 100% 2.4% 97.5% 0.1% 100% 7.7% 92.1% 0.2% 100% 2.0% 97.9% 0.1%	88.2% 100% 16.3% 83.7% 100% 2.4% 97.6% 100% 7.7% 92.3% 100% 2.0% 98.0%	-			
8.10b 8.11a 8.11b	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes No Missing Sum Malignancy - previous Yes No Missing Sum Malignancy - previous Yes No Missing Sum Diabetic ketoacidosis - last 12 months Yes No Missing Sum Diabetic ketoacidosis - previous	1256 2 1426 232 1191 3 1426 34 1390 2 1426 110 1313 3 1426 28 1396 2 1426	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100% 2.4% 97.5% 0.1% 100% 7.7% 92.1% 0.2% 100% 2.0% 97.9% 0.1% 100%	88.2% 100% 16.3% 83.7% 100% 2.4% 97.6% 100% 7.7% 92.3% 100% 2.0% 98.0% 100%				
8.10b 8.11a 8.11b	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes No Missing Sum Malignancy - previous Yes No Missing Sum Diabetic ketoacidosis - last 12 months Yes No Missing Sum Diabetic ketoacidosis - previous Yes No Missing Sum Diabetic ketoacidosis - previous Yes No Missing Sum Diabetic ketoacidosis - previous Yes	1256 2 1426 232 1191 3 1426 34 1390 2 1426 110 1313 3 1426 28 1396 2 1426	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100% 2.4% 97.5% 0.1% 100% 7.7% 92.1% 0.2% 100% 2.0% 97.9% 0.1% 100%	88.2% 100% 16.3% 83.7% 100% 2.4% 97.6% 100% 7.7% 92.3% 100% 2.0% 98.0% 100% 6.0%				
8.10b 8.11a 8.11b	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes No Missing Sum Malignancy - previous Yes No Missing Sum Diabetic ketoacidosis - last 12 months Yes No Missing Sum Diabetic ketoacidosis - previous Yes No	1256 2 1426 232 1191 3 1426 34 1390 2 1426 110 1313 3 1426 28 1396 2 1426	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100% 2.4% 97.5% 0.1% 100% 7.7% 92.1% 0.2% 100% 2.0% 97.9% 0.1% 100%	88.2% 100% 16.3% 83.7% 100% 2.4% 97.6% 100% 7.7% 92.3% 100% 2.0% 98.0% 100%				
8.10b 8.11a 8.11b	No Missing Sum Anxiety - previous Yes No Missing Sum Malignancy - last 12 months Yes No Missing Sum Malignancy - previous Yes No Missing Sum Diabetic ketoacidosis - last 12 months Yes No Missing Sum Diabetic ketoacidosis - previous Yes No Missing Sum Diabetic ketoacidosis - previous Yes No Missing Sum Diabetic ketoacidosis - previous Yes	1256 2 1426 232 1191 3 1426 34 1390 2 1426 110 1313 3 1426 28 1396 2 1426	88.1% 0.1% 100% 16.3% 83.5% 0.2% 100% 2.4% 97.5% 0.1% 100% 7.7% 92.1% 0.2% 100% 2.0% 97.9% 0.1% 100%	88.2% 100% 16.3% 83.7% 100% 2.4% 97.6% 100% 7.7% 92.3% 100% 2.0% 98.0% 100% 6.0%				

	SECTION 8. OTHER (COMPLICATION	NS/EVENTS	/COMORBIDITIE	S (contin	ued)			
Item	Field Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
8.13a	Hyperosmolar hyperglycaemic state - last	t 12 months							
	Yes	6	0.4%	0.4%					
	No	1418	99.4%	99.6%					
	Missing	2	0.1%		_				
	Sum	1426	100%	100%	_				
8.13b	Hyperosmolar hyperglycaemic state - pre								
	Yes	11	0.8%	0.8%					
	No	1413	99.1%	99.2%					
	Missing	2	0.1%		_				
	Sum	1426	100%	100%					
8.14a	Impaired awareness of hypoglycaemia - I								
	Yes	62	4.3%	4.4%					
	No	1362	95.5%	95.6%					
	Missing	2	0.1%		_				
	Sum	1426	100%	100%					
8.14b	Impaired awareness of hypoglycaemia - p								
	Yes	54	3.8%	3.8%					
	No	1370	96.1%	96.2%					
	Missing	2	0.1%		_				
	Sum	1426	100%	100%					
8.15a	Severe hypoglycaemia - last 12 months								
	Yes	60	4.2%	4.2%					
	No	1363	95.6%	95.8%					
	Missing	3	0.2%	4000/	-				
0.45.4	Sum	1426	100%	100%					
8.15.1	Number of episodes**	20	EQ 20/	E4.00/					
	1-2 episodes	32	53.3%	54.2%					
	3-5 episodes	15	25.0%	25.4%					
	>5 episodes	12	20.0%	20.3%					
	Missing	1 60	1.7%	4000/	-				
	Sum	•••	100%	100%					
0.456	**Of patients who reported severe hypoglycaemia	in the last 12 mon	เทร						
8.15b	Severe hypoglycaemia - previous	400	7.40/	7.40/					
	Yes	106	7.4%	7.4%					
	No Minaina	1317	92.4%	92.6%					
	Missing	3 1426	0.2%	4000/	-				
0.46	Sum	1420	100%	100%					
8.16	Liver disease	211	72 50/	75.00/					
	Mild Moderate/severe	211 67	73.5% 23.3%	75.9% 24.1%					
			23.3% 0.0%						
	Not applicable	0		0.0%					
	Missing	9 287	3.1%	4000/	-				
	Sum	201	100%	100%					

SECTION 8. OTHER COMPLICATIONS/EVENTS/COMORBIDITIES (continued)

	O.	LOTION O. OTTILIN O	OMII LIOATIO	NO/LVLINIO	COMORDIDITIE		ucuj			
Item	Field Category		Total	%	Relative %*	Median	Mean	SD	Min	Ma
8.17a	COVID-19 - last 12 mor	nths								
	Yes		335	23.5%	24.0%					
	No		1063	74.5%	76.0%					
	Missing		28	2.0%						
	Sum		1426	100%	100%	_				
8.17.1	COVID-19 hospital adr	nission - last 12 mon	ths**							
	Yes		27	8.1%	8.1%					
	No		306	91.3%	91.9%					
	Missing		2	0.6%						
	Sum		335	100%	100%					
	**Of patients who have	had COVID-19 in the I	ast 12 months							
8.17b	COVID-19 - previous									
	Yes		434	30.4%	31.1%					
	No		960	67.3%	68.9%					
	Missing		32	2.2%						
	Sum		1426	100%	100%					
8.17.2	COVID-19 hospital adr	nission - previous**								
	Yes		24	5.5%	5.6%					
	No		408	94.0%	94.4%					
	Missing		2	0.5%		_				
	Sum		434	100%	100%	_				

Sum 434
**Of patients who have had COVID-19 prior to the last 12 months

SECTION 9. MENTAL HEALTH SCREENING

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
9.1	Screen	ned for diabetes distress								
		Yes	67	4.7%	4.7%					
		No	1351	94.7%	95.3%					
		Missing	8	0.6%						
		Sum	1426	100%	100%	_				
9.2	Screen	ned for depression								
		Yes	143	10.0%	10.1%					
		No	1275	89.4%	89.9%					
		Missing	8	0.6%						
		Sum	1426	100%	100%	_				
9.3	Screen	ned for anxiety								
		Yes	124	8.7%	8.7%					
		No	1294	90.7%	91.3%					
		Missing	8	0.6%						
		Sum	1426	100%	100%	_				

PATIENT HEALTH & WELL-BEING QUESTIONNAIRE	Max
Total % Relative %* Median Mean SD Mi	Max
Currently smoke	Мах
Currently smoke Not currently smoking 948 66.5% 88.4% Missing 354 24.8% Sum 1426 100% 100% Q1.1.1 Smoking status - past** Previously smoked 328 34.6% 36.8% Previously did not smoke 563 59.4% 63.2% Missing 57 6.0% Sum 948 100% 100% **Of patients who are not current smokers Q1.2 COVID-19 vaccination in the last 6 months Yes 425 29.8% 39.4% No 655 45.9% 60.6% Missing 346 24.3% Sum 1426 100% 100%	
Not currently smoking 948 66.5% 88.4%	
Missing 354 24.8% Sum 1426 100% 100% Q1.1.1 Smoking status - past** Previously smoked 328 34.6% 36.8% Previously did not smoke 563 59.4% 63.2% Missing 57 6.0% Sum 948 100% 100% ***Of patients who are not current smokers Q1.2 COVID-19 vaccination in the last 6 months Yes 425 29.8% 39.4% No 655 45.9% 60.6% Missing 346 24.3% Sum 1426 100% 100%	
Sum	
Q1.1.1 Smoking status - past** Previously smoked 328 34.6% 36.8% Previously did not smoke 563 59.4% 63.2% Missing 57 6.0% Sum 948 100% 100% **Of patients who are not current smokers Q1.2 COVID-19 vaccination in the last 6 months Yes 425 29.8% 39.4% No 655 45.9% 60.6% Missing 346 24.3% Sum 1426 100% 100%	
Previously smoked 328 34.6% 36.8% Previously did not smoke 563 59.4% 63.2% Missing 57 6.0% Sum 948 100% 100% ***Of patients who are not current smokers Q1.2 COVID-19 vaccination in the last 6 months Yes 425 29.8% 39.4% No 655 45.9% 60.6% Missing 346 24.3% Sum 1426 100% 100%	
Previously did not smoke 563 59.4% 63.2% Missing 57 6.0% Sum 948 100% 100% **Of patients who are not current smokers Q1.2 COVID-19 vaccination in the last 6 months Yes 425 29.8% 39.4% No 655 45.9% 60.6% Missing 346 24.3% Sum 1426 100% 100%	
Missing 57 6.0% Sum 948 100% 100% **Of patients who are not current smokers Q1.2 COVID-19 vaccination in the last 6 months Yes 425 29.8% 39.4% No 655 45.9% 60.6% Missing 346 24.3% Sum 1426 100% 100%	
Sum	
**Of patients who are not current smokers Q1.2 COVID-19 vaccination in the last 6 months Yes	
Q1.2 COVID-19 vaccination in the last 6 months Yes 425 29.8% 39.4% No 655 45.9% 60.6% Missing 346 24.3% Sum 1426 100% 100%	
Yes 425 29.8% 39.4% No 655 45.9% 60.6% Missing 346 24.3% Sum 1426 100% 100%	
No 655 45.9% 60.6% Missing 346 24.3% Sum 1426 100% 100%	
Missing 346 24.3% Sum 1426 100% 100%	
Sum 1426 100% 100%	
1.20 100/0	
Q1.3 Influenza vaccination in the last 12 months	
Yes 748 52.5% 69.3%	
No 332 23.3% 30.7%	
Missing 346 24.3%	
Sum 1426 100% 100%	
Q1.4 Pneumococcal vaccination is up to date	
Yes 267 18.7% 24.8%	
No 354 24.8% 32.9%	
Unsure 454 31.8% 42.2%	
Missing 351 24.6%	
Sum 1426 100% 100%	

SECTION 2. HEALTH PROFESSIONAL ATTENDANCES (LAST 12 MONTHS)

	SECTION 2. HEALTH			•		•			
Item	Field Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
Q2.1	Attended endocrinologist								
	Yes	710	49.8%	65.6%					
	No	373	26.2%	34.4%					
	Missing	343	24.1%						
	Sum	1426	100%	100%	_				
Q2.2	Attended diabetes educator/nurse practitio								
	Yes	718	50.4%	66.2%					
	No	367	25.7%	33.8%					
	Missing	341	23.9%	00.070					
	Sum	1426	100%	100%	-				
Q2.3	Attended dietitian	1420	100 /0	100 /0					
QZ.J	Yes	333	23.4%	30.7%					
	No Mination	750	52.6%	69.3%					
	Missing	343	24.1%	4000/	_				
	Sum	1426	100%	100%					
Q2.4	Attended podiatrist								
	Yes	633	44.4%	58.4%					
	No	450	31.6%	41.6%					
	Missing	343	24.1%		_				
	Sum	1426	100%	100%					
Q2.5	Attended ophthalmologist								
	Yes	411	28.8%	38.4%					
	No	659	46.2%	61.6%					
	Missing	356	25.0%						
	Sum	1426	100%	100%	-				
Q2.6	Attended optometrist								
4	Yes	789	55.3%	73.2%					
	No	289	20.3%	26.8%					
	Missing	348	24.4%	20.070					
	Sum	1426	100%	100%	-				
Q2.7	Attended psychologist/psychiatrist	1420	100 /0	100 /0					
QZ.1	Yes	129	9.0%	12.0%					
		950	66.6%						
	No Minain n			88.0%					
	Missing	347	24.3%	4000/	-				
000	Sum	1426	100%	100%					
Q2.8	Attended social worker		= 40/	- 00/					
	Yes	77	5.4%	7.2%					
	No	999	70.1%	92.8%					
	Missing	350	24.5%		_				
	Sum	1426	100%	100%					
Q2.9	Attended dentist								
	Yes	486	34.1%	45.2%					
	No	590	41.4%	54.8%					
	Missing	350	24.5%						
	Sum	1426	100%	100%	-				
Q2.10	Attended physiologist/physiotherapist								
	Yes	234	16.4%	21.6%					
	No	850	59.6%	78.4%					
	Missing	342	24.0%	70.7/0					
	Sum	1426	100%	100%	-				
Q2.11	Needed an ambulance	1420	10070	10070					
س ۱۱ کی		60	A 20/	E E0/					
	Yes	60 1025	4.2%	5.5%					
	No	1025	71.9%	94.5%					
	Missing	341	23.9%		_				
	Sum	1426	100%	100%					
Q2.12	Attended the emergency department								
	Yes	93	6.5%	8.6%					
	No	989	69.4%	91.4%					
	Missing	344	24.1%		_				
	Sum	1426	100%	100%	_				

SECTION 3. MEDICATION USE

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
Q3.1	Ever fo	orget to take medications in the last 2 v	weeks							
		Yes	185	13.0%	17.1%					
		No	897	62.9%	82.9%					
		Missing	344	24.1%		_				
		Sum	1426	100%	100%	_				
Q3.1.1	Numbe	er of times per week**								
		Number of times per week provided	164	88.6%	100.0%	2.0	3.4	3.8	1.0	30.0
		Missing	21	11.4%		_				
		Sum	185	100%	100%	_				

^{**}Of patients who forgot to take medications

SECTION 4. FOOT CARE

Item	Field	Category		Total	%	Relative %*	Median	Mean	SD	Min	Max
Q4.1	Feet ch	necked by a health pro	fessional in the l	ast 12 mo	nths						
		Yes		735	51.5%	67.8%					
		No		349	24.5%	32.2%					
		Missing		342	24.0%						
		Sum		1426	100%	100%	_				
Q4.2	Self fee	et check									
		Daily		372	26.1%	35.1%					
		Weekly		270	18.9%	25.5%					
		Monthly		147	10.3%	13.9%					
		Rarely/Never		270	18.9%	25.5%					
		Missing		367	25.7%						
		Sum		1426	100%	100%	_				

SECTION 5. NUTRITION/DIET MANAGEMENT

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
Q5.1	Know v	what foods are best to eat								
		Yes	1009	70.8%	93.3%					
		No	72	5.0%	6.7%					
		Missing	345	24.2%						
		Sum	1426	100%	100%	_				
Q5.2	Enougl	h time to prepare healthy meals								
		Yes	914	64.1%	84.6%					
		No	166	11.6%	15.4%					
		Missing	346	24.3%		_				
		Sum	1426	100%	100%					
Q5.3	Costs t	oo much to eat healthy meals								
		Yes	387	27.1%	36.0%					
		No	689	48.3%	64.0%					
		Missing	350	24.5%		_				
		Sum	1426	100%	100%					
Q5.4	(T1DM)	Hard to count carbs/weigh food								
		Yes	135	34.0%	46.4%					
		No	156	39.3%	53.6%					
		Missing	106	26.7%		_				
		Sum	397	100%	100%					

SECTION 6. PHYSICAL ACTIVITY

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
Q6.1	Modera	ate or vigorous intensity physical								
		150 mins/week or more	359	25.2%	33.1%					
		Less than 150 mins/week	355	24.9%	32.8%					
		Rarely/never	369	25.9%	34.1%					
		Missing	343	24.1%		_				
		Sum	1426	100%	100%	_				
Q6.2	Muscle	e strengthening								
		Yes	364	25.5%	33.7%					
		No	715	50.1%	66.3%					
		Missing	347	24.3%		_				
		Sum	1426	100%	100%					

MISSING DATA

TABLE 1. OVERALL MISSING DATA

		Amo	unt of missin	g data in vari	ables	
	0-5%	6-10%	11-15%	16-20%	21-40%	>40%
Proportion of variables with missing data*	71.0%	3.8%	0.8%	0.0%	21.4%	3.1%

^{*}Relates to the proportion of variables/fields according to the amount of missing data in each variable, e.g. 71.0% of variables had 5% or less of missing data.

TABLE 2. MISSING DATA BY FIELD AND DATA COLLECTION METHOD

0 "		All (n=1426)		Paper-based (n=714)		REDCap	
Question No.	Question					(n=712)	
			%	n	%	n	%
Patient Der	mographics						
1.0	How was the consultation conducted?	6	0.4	2	0.3	4	0.6
1.1	Date of birth	1	0.1	1	0.1	0	0.0
1.2	Sex	0	0.0	0	0.0	0	0.0
1.2.1	Currently pregnant (of females aged 18-55 years)	2	0.9	1	0.8	1	1.1
1.3	Date of visit	0	0.0	0	0.0	0	0.0
1.4	NDSS registrant	13	0.9	2	0.3	11	1.5
1.5	Aboriginal/Torres Strait Islander	1	0.1	1	0.1	0	0.0
1.6	Initial visit	5	0.4	3	0.4	2	0.3
1.7	Interpreter required	0	0.0	0	0.0	0	0.0
1.8	Main language spoken at home	6	0.4	0	0.0	6	0.8
1.9	DVA	5	0.4	3	0.4	2	0.3
1.10	Country of birth	7	0.5	4	0.6	3	0.4
1.11	Residential postcode	7	0.5	5	0.7	2	0.3
Diabetes T	ype & Management						
2.1	Date of diagnosis	10	0.7	3	0.4	7	1.0
2.2	Type of diabetes	0	0.0	0	0.0	0	0.0
2.3	Blood glucose monitoring	2	0.1	0	0.0	2	0.3
2.3.1	Finger prick - Check as often as recommended	5	0.6	4	0.9	1	0.2
2.3.2	Finger prick - Number of times a day	30	3.3	7	1.6	23	5.1
2.3.3	Was the sensor worn for ≥14 days in the last 3 months?	1	0.3	0	0.0	1	0.6
2.3.3.1	If YES, percentage of time sensor was active	6	1.7	4	2.0	2	1.3
2.4	Management method	2	0.1	0	0.0	2	0.3
2.4.1	Insulin - duration	27	2.7	15	3.0	12	2.4
2.4.2	Insulin - mode	2	0.2	0	0.0	2	0.4
Weight & H	leight						
3.1	Weight	36	2.5	19	2.7	17	2.4
3.2	Height	72	5.0	44	6.2	28	3.9
Blood Pres	sure						
4.1	Blood pressure	110	7.7	78	10.9	32	4.5
4.1.1	Measured in clinic or self-reported	49	3.7	47	7.4	2	0.3
4.2	Anti-hypertensive treatment	0	0.0	0	0.0	0	0.0
4.2.1	Anti-hypertensive medications	0	0.0	0	0.0	0	0.0
Renal Fund	ction & Blood Glucose Control						
5.1	HbA1c	45	3.2	28	3.9	17	2.4
5.1.1	HbA1c - Test date	520	37.7	208	30.3	312	45.5
5.2	eGFR	468	32.8	220	30.8	248	34.8

Ougatian			All		Paper-based		Сар
Question No.	Question	(n=1	426)	(n=714)		(n=712)	
		n	%	n	%	n	%
5.3	Serum creatinine	118	8.3	69	9.7	49	6.9
5.4a	Urinary albumin	507	35.6	298	41.7	209	29.4
5.4b	Urinary protein	1277	89.6	622	87.1	655	92.0
	ns & Lipids						
6.1	Aspirin	3	0.2	1	0.1	2	0.3
6.2	Other anti-platelets	3	0.2	1	0.1	2	0.3
6.3	Anti-coagulants	3	0.2	1	0.1	2	0.3
6.4	Lipid modifying therapy	3	0.2	1	0.1	2	0.3
6.4.1	On lipid modifying therapy - Statin	0	0.0	0	0.0	0	0.0
6.4.2	On lipid modifying therapy - Fibrate	5	0.5	4	0.9	1	0.2
6.4.3	On lipid modifying therapy - Ezetimibe	4	0.4	4	0.9	0	0.0
6.4.4	On lipid modifying therapy - Fish oil	3	0.3	3	0.7	0	0.0
6.4.5	On lipid modifying therapy - PCSK9 inhibitor	4	0.4	4	0.9	0	0.0
6.5	Lipids measured	0	0.0	0	0.0	0	0.0
6.5.1	Lipids measured - Total cholesterol	4	0.4	1 70	0.2	3	0.5
6.5.2	Lipids measured - LDL	118	10.9	73	14.3	45	8.0
6.5.3	Lipids measured - HDL	99	9.2	55	10.7	44	7.8
6.5.4	Lipids measured - Triglycerides	11	1.0	8	1.6	3	0.5
	Related Eye & Foot Complications						• • • • • • • • • • • • • • • • • • • •
7.1a	Retinopathy - last 12 months	4	0.3	2	0.3	2	0.3
7.1b	Retinopathy - previous	4	0.3	2	0.3	2	0.3
7.2a 7.2b	Retinopathy treatment - last 12 months	3	0.2	1	0.1	2	0.3
7.3a	Retinopathy treatment - previous Cataract - last 12 months	2	0.2	0	0.1	2	0.3
7.3b		2	0.1	0	0.0	2	0.3
7.4a	Cataract - previous Blindness - last 12 months	2		0		2	
7.4a 7.4b	Blindness - previous	3	0.1	1	0.0 0.1	2	0.3
7.40 7.5a	Peripheral neuropathy - last 12 months	2	0.2	0	0.0	2	0.3
7.5b	Peripheral neuropathy - previous	2	0.1	0	0.0	2	0.3
7.6a	Foot ulceration - last 12 months	2	0.1	0	0.0	2	0.3
7.6b	Foot ulceration - previous	2	0.1	0	0.0	2	0.3
7.7a	Lower limb amputation - last 12 months	2	0.1	0	0.0	2	0.3
7.7.1	Minor/major - last 12 months	0	0.0	0	0.0	0	0.0
7.7b	Lower limb amputation - previous	2	0.1	0	0.0	2	0.3
7.7.2	Minor/major - previous	0	0.0	0	0.0	0	0.0
	plications/Events/Comorbidities	•					
8.1a	Cerebral stroke - last 12 months	2	0.1	0	0.0	2	0.3
8.1b	Cerebral stroke - previous	4	0.3	2	0.3	2	0.3
8.2a	Myocardial infarction - last 12 months	2	0.1	0	0.0	2	0.3
8.2b	Myocardial infarction - previous	3	0.2	1	0.1	2	0.3
8.3a	CABG/Angioplasty - last 12 months	2	0.1	0	0.0	2	0.3
8.3b	CABG/Angioplasty - previous	2	0.1	0	0.0	2	0.3
8.4a	Congestive cardiac failure - last 12 months	2	0.1	0	0.0	2	0.3
8.4b	Congestive cardiac failure - previous	2	0.1	0	0.0	2	0.3
	<u> </u>						


Ougotion			All .	Paper	-based	RED	Сар
Question No.	Question	(n=1	1426)	(n=714)		(n=712)	
		n	%	n	%	n	%
8.5a	Peripheral vascular disease - last 12 months	2	0.1	0	0.0	2	0.3
8.5b	Peripheral vascular disease - previous	2	0.1	0	0.0	2	0.3
8.6a	End stage renal disease - last 12 months	2	0.1	0	0.0	2	0.3
8.6b	End stage renal disease - previous	2	0.1	0	0.0	2	0.3
8.7a	Sexual dysfunction - last 12 months	18	1.3	1	0.1	17	2.4
8.7b	Sexual dysfunction - previous	18	1.3	0	0.0	18	2.5
8.8a	Dementia - last 12 months	3	0.2	1	0.1	2	0.3
8.8b	Dementia - previous	2	0.1	0	0.0	2	0.3
8.9a	Depression - last 12 months	3	0.2	0	0.0	3	0.4
8.9b	Depression - previous	3	0.2	0	0.0	3	0.4
8.10a	Anxiety - last 12 months	2	0.1	0	0.0	2	0.3
8.10b	Anxiety - previous	3	0.2	0	0.0	3	0.4
8.11a	Malignancy - last 12 months	2	0.1	0	0.0	2	0.3
8.11b	Malignancy - previous	3	0.2	1	0.1	2	0.3
8.12a	Diabetic ketoacidosis - last 12 months	2	0.1	0	0.0	2	0.3
8.12b	Diabetic ketoacidosis - previous	2	0.1	0	0.0	2	0.3
8.13a	Hyperosmolar hyperglycaemic state - last 12 months	2	0.1	0	0.0	2	0.3
8.13b	Hyperosmolar hyperglycaemic state - previous	2	0.1	0	0.0	2	0.3
8.14a	Impaired awareness of hypoglycaemia - last 12 months	2	0.1	0	0.0	2	0.3
8.14b	Impaired awareness of hypoglycaemia - previous	2	0.1	0	0.0	2	0.3
8.15a	Severe hypoglycaemic state - last 12 months	3	0.2	1	0.1	2	0.3
8.15.1	Severe hypoglycaemic state episodes - last 12 months	1	1.7	1	2.9	0	0.0
8.15b	Severe hypoglycaemic state - previous	3	0.2	1	0.1	2	0.3
8.16	Liver disease	9	0.6	7	1.0	2	0.3
8.17a	COVID-19 - last 12 months	28	2.0	10	1.4	18	2.5
8.17.1	COVID-19 hospitalisation- last 12 months	2	0.6	2	1.4	0	0.0
8.17b	COVID-19 - previous	32	2.2	15	2.1	17	2.4
8.17.2	COVID-19 hospitalisation - previous	2	0.5	2	0.5	0	0.0
Mental Hea	alth Screening						
9.1	Screened for diabetes distress	8	0.6	2	0.3	6	0.8
9.2	Screened for depression	8	0.6	2	0.3	6	0.8
9.3	Screened for anxiety	8	0.6	2	0.3	6	0.8


Ougetien		A	All .	Paper	-based	RED	Сар
Question No.	Question	(n=1	1426)	(n=714)		(n=	712)
		n	%	n	%	n	%
Patient Qu	estionnaire - Smoking & Vaccination Status						
Q1.1	Currently smoke	354	24.8	172	24.1	182	25.6
Q1.1.1	Previously smoked	57	6.0	52	10.7	5	1.1
Q1.2	COVID-19 vaccination - last 6 months	346	24.3	163	22.8	183	25.7
Q1.3	Flu vaccination - last 12 months	346	24.3	164	23.0	182	25.6
Q1.4	Pneumococcal vaccination - up to date	351	24.6	169	23.7	182	25.6
Patient Qu	estionnaire - Health Professional Attendances						
Q2.1	Endocrinologist	343	24.1	163	22.8	180	25.3
Q2.2	Diabetes educator/Nurse practitioner	341	23.9	160	22.4	181	25.4
Q2.3	Dietitian	343	24.1	161	22.5	182	25.6
Q2.4	Podiatrist	343	24.1	163	22.8	180	25.3
Q2.5	Ophthalmologist	356	25.0	176	24.6	180	25.3
Q2.6	Optometrist	348	24.4	163	22.8	185	26.0
Q2.7	Psychologist/Psychiatrist	347	24.3	166	23.2	181	25.4
Q2.8	Social worker	350	24.5	167	23.4	183	25.7
Q2.9	Dentist	350	24.5	169	23.7	181	25.4
Q2.10	Exercise physiologist/Physiotherapist	342	24.0	161	22.5	181	25.4
Q2.11	Needed an Ambulance for diabetes	341	23.9	160	22.4	181	25.4
Q2.12	Attended the Emergency Department for diabetes	344	24.1	163	22.8	181	25.4
Patient Qu	estionnaire - Medication Use						
Q3.1	Forget to take medications	344	24.1	162	22.7	182	25.6
Q3.1.1	Forget to take medications - Times per week	21	1.5	18	2.5	3	0.4
Patient Qu	estionnaire - Foot Care						
Q4.1	Feet check	342	24.0	162	22.7	180	25.3
Q4.2	Feet self-check	367	25.7	181	25.4	186	26.1
Patient Qu	estionnaire - Nutrition/Diet Management						
Q5.3	Not knowing what foods are best to eat	345	24.2	163	22.8	182	25.6
Q5.4	Don't have enough time to prepare healthy meals	346	24.3	164	23.0	182	25.6
Q5.5	Costs too much to eat well	350	24.5	168	23.5	182	25.6
Q5.6	(T1DM) Too hard to count carbs/weigh food	954	66.9	457	64.0	497	69.8
Patient Qu	estionnaire - Physical Activity						
Q5.1	Moderate/vigorous intensity physical activity	637	44.7	323	45.2	314	44.1
Q5.2	Muscle strengthening exercise	347	24.3	165	23.1	182	25.6


DESCRIPTIVE REPORT


Mean age and median duration by diabetes type


Dishetes type		Α	ge (years		Duration (years)			
Diabetes type	n	Mean	SD	Min	Max	n	Median	IQR
T1DM	396	45.9	17.6	18.0	86.5	397	19.5	9.4 - 31.7
T2DM	988	66.0	13.1	18.5	99.5	978	14.6	7.7 - 23.5
Other	38	58.9	16.5	27.5	88.6	38	6.5	2.5 - 13.1
Don't know	3	43.8	17.8	25.2	60.7	3	5.2	2.8 - 14.3
Total	1425	60.2	17.1	18.0	99.5	1416	15.5	8.0 - 23.7














Sex by diabetes type

Diabetes type		Males			Females		To	otal
	n	R%	C%	n	R%	C%	n	%
T1DM	201	50.6	25.6	196	49.4	30.6	397	27.8
T2DM	558	56.5	71.2	429	43.4	66.9	988	69.3
Other	24	63.2	3.1	14	36.8	2.2	38	2.7
Don't know	1	33.3	0.1	2	66.7	0.3	3	0.2
Total	784	55.0		641	45.0		1426	

Currently pregnant* by diabetes type

Dishetes type		Yes			No		To	tal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	12	9.2	85.7	118	90.8	55.9	130	57.8
T2DM	2	2.3	14.3	84	97.7	39.8	86	38.2
Other	0	0.0	0.0	7	100.0	3.3	7	3.1
Don't know	0	0.0	0.0	2	100.0	0.9	2	0.9
Total	14	6.2		211	93.8		225	

^{*}Females aged 18-55 years

Consultation method by diabetes type

							•				
Dichetee type		In person			Video			Phone		Total	
Diabetes type	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	341	86.3	28.0	24	6.1	42.9	30	7.6	20.4	395	27.9
T2DM	847	86.1	69.6	28	2.8	50.0	109	11.1	74.1	984	69.4
Other	26	68.4	2.1	4	10.5	7.1	8	21.1	5.4	38	2.7
Don't know	3	100.0	0.2	0	0.0	0.0	0	0.0	0.0	3	0.2
Total	1217	85.9		56	4.0		147	10.4		1420	

Initial visit by diabetes type

Dishetes type		Yes			No			otal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	31	7.8	21.7	365	92.2	28.6	396	27.9
T2DM	108	11.0	75.5	877	89.0	68.6	985	69.3
Other	4	10.8	2.8	33	89.2	2.6	37	2.6
Don't know	0	0.0	0.0	3	100.0	0.2	3	0.2
Total	143	10.1		1278	89.9		1421	

X-axis: All sites (Descending order)

Main language English, spoken at home by diabetes type

Dishetes tune		Yes			No		To	tal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	365	92.2	30.6	31	7.8	13.6	396	27.9
T2DM	797	81.1	66.9	186	18.9	81.6	983	69.2
Other	29	76.3	2.4	9	23.7	3.9	38	2.7
Don't know	1	33.3	0.1	2	66.7	0.9	3	0.2
Total	1192	83.9		228	16.1		1420	

Interpreter required by diabetes type

Dishetes type		Yes			No		To	tal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	11	2.8	15.3	386	97.2	28.5	397	27.8
T2DM	57	5.8	79.2	931	94.2	68.8	988	69.3
Other	4	10.5	5.6	34	89.5	2.5	38	2.7
Don't know	0	0.0	0.0	3	100.0	0.2	3	0.2
Total	72	5.0		1354	95.0		1426	

Aborignal/Torres Strait Islander status by diabetes type

Diabetes type		Yes			No		To	tal
	n	R%	C%	n	R%	C%	n	%
T1DM	13	3.3	28.9	384	96.7	27.8	397	27.9
T2DM	29	2.9	64.4	958	97.1	69.4	987	69.3
Other	3	7.9	6.7	35	92.1	2.5	38	2.7
Don't know	0	0.0	0.0	3	100.0	0.2	3	0.2
Total	45	3.2		1380	96.8		1425	

Australian born by diabetes type

Diabetes type		Yes			No		To	tal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	313	78.8	32.8	84	21.2	18.1	397	28.0
T2DM	619	63.0	64.9	364	37.0	78.3	983	69.3
Other	21	58.3	2.2	15	41.7	3.2	36	2.5
Don't know	1	33.3	0.1	2	66.7	0.4	3	0.2
Total	954	67.2		465	32.8		1419	

NDSS registrant by diabetes type


Dishetes tune		Yes			No		To	otal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	385	97.2	28.8	11	2.8	14.1	396	28.0
T2DM	915	93.8	68.5	61	6.3	78.2	976	69.1
Other	33	86.8	2.5	5	13.2	6.4	38	2.7
Don't know	2	66.7	0.1	1	33.3	1	3	0.2
Total	1335	94.5		78	5.5		1413	


DVA by diabetes type


Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	3	0.8	33.3	393	99.2	27.8	396	27.9
T2DM	6	0.6	66.7	978	99.4	69.3	984	69.2
Other	0	0.0	0.0	38	100.0	2.7	38	2.7
Don't know	0	0.0	0.0	3	100.0	0	3	0.2
Total	9	0.6		1412	99.4		1421	

Mean BMI by diabetes type

Diabetes type		BMI (kg/m²)									
Diabetes type	n	Mean	SD	Min	Max						
T1DM	369	28.6	6.1	16.1	55.2						
T2DM	936	32.3	7.5	15.0	69.9						
Other	37	27.7	6.2	18.4	45.7						
Don't know	3	26.8	4.3	21.9	30.1						
Total	1345	31.1	7.3	15.0	69.9						











BMI by diabetes type


Diabetes type	•	<25 (kg/m²	2)	2	5-30 (kg/m	n ²)	2	≥30 (kg/m²	²)	To	otal
Diabetes type	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	115	31.2	45.6	124	33.6	29.7	130	35.2	19.3	369	27.4
T2DM	124	13.2	49.2	277	29.6	66.3	535	57.2	79.3	936	69.6
Other	12	32.4	4.8	16	43.2	3.8	9	24.3	1.3	37	2.8
Don't know	1	33.3	0.4	1	33.3	0.2	1	33.3	0.1	3	0.2
Total	252	18.7		418	31.1		675	50.2		1345	


























Methods of blood glucose monitoring


Dishetes type	None	(not grap	ohed)	Fing	er pricking	only		CGM only	1	Finge	r pricking	& CGM	To	tal
Diabetes type	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	1	0.3	0.6	69	18.4	7.9	306	81.4	84.3	21	5.6	87.5	376	26.9
T2DM	157	16.0	96.9	776	78.9	88.7	51	5.2	14.0	2	0.2	8.3	984	70.3
Other	4	10.5	2.5	28	73.7	3.2	6	15.8	1.7	0	0.0	0.0	38	2.7
Don't know	0	0.0	0.0	2	100.0	0.2	0	0.0	0.0	1	50.0	4.2	2	0.1
Total	162	11.6		875	62.5		363	25.9		24	1.7		1400	


^{*}Multiple methods reported by some patients


























Proportion of time using active blood glucose monitoring sensors*


Dishetes type		<70%			≥70%		To	otal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	44	15.0	36.7	249	85.0	85.6	293	20.9
T2DM	10	21.7	8.3	36	78.3	12.4	46	3.3
Other	1	16.7	0.8	5	83.3	1.7	6	0.4
Don't know	0	0.0	0.0	1	100.0	0.3	1	0.1
Total	55	15.9		291	84.1		346	


^{*}Of patients using flash/continuous glucose monitoring, and sensor worn for ≥14 days in the last 3 months


















Smoking status by diabetes type


Dichetee type	Cu	rrent smo	ker	P	ast smok	er	Ne	ever smok	ed	To	tal
Diabetes type	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	44	15.6	35.5	68	24.1	20.7	170	60.3	30.2	282	27.8
T2DM	76	10.8	61.3	246	35.0	75.0	380	54.1	67.5	702	69.2
Other	4	14.3	3.2	12	42.9	3.7	12	42.9	2.1	28	2.8
Don't know	0	0.0	0.0	2	66.7	0.6	1	33.3	0.2	3	0.3
Total	124	12.2		328	32.3		563	55.5		1015	



























Age by blood pressure level

A = 0	<13	0/80	≥13	0/80	<14	0/90	≥14	0/90
Age	n	C%	n	C%	n	C%	n	C%
≤60 years	165	40.2	341	37.6	353	41.3	153	33.1
>60 years	244	59.5	565	62.4	500	58.5	309	66.9
Total	410		906		854		462	












Treatment by diabetes type


Diabetes type		Diet only			Tablets			Insulin		Ins	ulin & tab	lets		Injectable not graphe	
	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%
T1DM	0	0.0	0.0	0	0.0	0.0	346	87.2	77.9	44	11.1	13.3	0	0.0	0.0
T2DM	40	4.0	97.6	248	25.1	96.5	79	8.0	17.8	278	28.1	84.2	7	0.7	77.8
Other	1	2.6	2.4	9	23.7	3.5	18	47.4	4.1	8	21.1	2.4	2	5.3	22.2
Don't know	0	0.0	0.0	0	0.0	0.0	1	33.3	0.2	0	0.0	0.0	0	0.0	0.0
Total	41	2.9		257	18.0		444	31.1		330	23.1		9	0.6	


Diabetes type	•	tables & ir ot graphe		Injec	tables & t	ablets	Inject	tables, tab insulin	lets &	(1	Unstated not graphe	-	To	otal
	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	3	0.8	15.0	0	0.0	0.0	4	1.0	2.1	0	0.0	0.0	397	27.8
T2DM	16	1.6	80.0	131	13.3	100.0	187	18.9	97.4	2	0.2	100.0	988	69.3
Other	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	38	2.7
Don't know	1	33.3	5.0	0	0.0	0.0	1	33.3	0.5	0	0.0	0.0	3	0.2
Total	20	1.4		131	9.2		192	13.5		2	0.1		1426	


















Metformin use by diabetes type


Dishetes tune		Yes			No		To	otal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	42	10.6	5.3	355	89.4	55.9	397	27.8
T2DM	732	74.1	92.5	256	25.9	40.3	988	69.3
Other	16	42.1	2.0	22	57.9	3.5	38	4.0
Don't know	1	33.3	0.1	2	66.7	0.3	3	0.2
Total	791	55.5		635	44.5		1426	


















SGLT2 inhibitor use by diabetes type


Dishetes tune		Yes			No		To	tal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	15	3.8	3.7	382	96.2	37.6	397	27.8
T2DM	391	39.6	95.6	597	60.4	58.7	988	69.3
Other	3	7.9	0.7	35	92.1	3.4	38	2.7
Don't know	0	0.0	0.0	3	100.0	0.3	3	0.2
Total	409	28.7		1017	71.3		1426	


















GLP1/GIP agonist use by diabetes type


Dishetes type		Yes			No		To	tal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	7	1.8	2.0	390	98.2	36.3	397	27.8
T2DM	341	34.5	96.9	647	65.5	60.2	988	69.3
Other	2	5.3	0.6	36	94.7	3.4	38	2.7
Don't know	2	66.7	0.6	1	33.3	0.1	3	0.2
Total	352	24.7		1074	75.3		1426	














DPP4 inhibitor use by diabetes type

Dichetee tune		Yes			No		To	tal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	3	0.8	1.2	394	99.2	33.6	397	27.8
T2DM	246	24.9	96.9	742	75.1	63.3	988	69.3
Other	5	13.2	2.0	33	86.8	2.8	38	2.7
Don't know	0	0.0	0.0	3	100.0	0.3	3	0.2
Total	254	17.8		1172	82.2		1426	

Sulphonylurea use by diabetes type

Diabetes type		Yes			No		To	tal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	0	0.0	0.0	397	100.0	33.4	397	27.8
T2DM	233	23.6	98.7	755	76.4	63.4	988	69.3
Other	3	7.9	1.3	35	92.1	2.9	38	2.7
Don't know	0	0.0	0.0	3	100.0	0.3	3	0.2
Total	236	16.5		1190	83.5		1426	

Acarbose use by diabetes type


Dichetee type		Yes			No		Total		
Diabetes type	n	R%	C%	n	R%	C%	n	%	
T1DM	0	0.0	0.0	397	100.0	28.1	397	27.8	
T2DM	12	1.2	92.3	976	98.8	69.1	988	69.3	
Other	1	2.6	7.7	37	97.4	2.6	38	2.7	
Don't know	0	0.0	0.0	3	100.0	0.2	3	0.2	
Total	13	0.9		1413	99.1		1426		


Thiazolidinedione use by diabetes type


Diabetes type		Yes			No		Total		
Diabetes type	n	R%	C%	n	R%	C%	n	%	
T1DM	0	0.0	0.0	397	100.0	27.9	397	27.8	
T2DM	1	0.1	50.0	987	99.9	69.3	988	69.3	
Other	1	2.6	50.0	37	97.4	2.6	38	2.7	
Don't know	0	0.0	0.0	3	100.0	0.2	3	0.2	
Total	2	0.1		1424	99.9		1426		


Insulin use by diabetes type

Diabetes type		Yes			No		Total		
Diabetes type	n	R%	C%	n	R%	C%	n	%	
T1DM	397	100.0	40.3	0	0.0	0.0	397	27.8	
T2DM	560	56.7	56.8	428	43.3	97.3	988	69.3	
Other	26	68.4	2.6	12	31.6	2.7	38	2.7	
Don't know	3	100.0	0.3	0	0.0	0.0	3	0.2	
Total	986	69.1		440	30.9		1426		












Number of glucose lowering medications by diabetes type


Dishetes type	0 (Not graph	ed)		1			2		3			≥4 (Not graphed)		
Diabetes type	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%
T1DM	0	0.0	0.0	346	87.2	64.0	37	9.3	13.4	12	3.0	3.6	2	0.5	0.9
T2DM	42	4.3	97.7	171	17.3	31.6	228	23.1	82.3	319	32.3	95.8	228	23.1	98.3
Other	1	2.6	2.3	23	60.5	4.3	11	28.9	4.0	1	2.6	0.3	2	5.3	0.9
Don't know	0	0.0	0.0	1	33.3	0.2	1	33.3	0.4	1	33.3	0.3	0	0.0	0.0
Total	43	3.0		541	37.9		277	19.4		333	23.4		232	16.3	








10	tal
n	%
397	27.8
988	69.3
38	2.7
3	0.2
1426	
	397 988 38 3

















Modes of insulin* by diabetes type


Dichetee type		Basal		Basal bolus		Pre-mixed insulin			Pump			Total		
Diabetes type	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	11	2.7	9.2	267	65.8	62.1	18	4.4	5.0	110	27.1	99.1	406	39.8
T2DM	104	17.8	86.7	149	25.5	34.7	330	56.5	91.9	1	0.2	0.9	584	57.3
Other	4	14.8	3.3	12	44.4	2.8	11	40.7	3.1	0	0.0	0.0	27	2.6
Don't know	1	33.3	0.8	2	66.7	0.5	0	0.0	0.0	0	0.0	0.0	3	0.3
Total	120	11.8		430	42.2		359	35.2		111	10.9		1020	


^{*}Patients taking insulin (multiple modes of insulin were reported for some patients)






























Types of insulin pumps* by diabetes type


Diabetes type		itomated (d Loop Sy		CSII automated (Other)			CSII	Non-autor	Total		
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	67	61.5	55.8	15	13.8	93.8	27	24.8	100.0	109	10.7
T2DM	0	0.0	0.0	1	100.0	6.3	0	0.0	0.0	1	0.1
Other	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0.0
Don't know	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0.0
Total	67	60.9		16	14.5		27	24.5		110	


^{*}Of patients using insulin with pump


HbA1c (%) by diabetes type


Diabetes type	n	Mean	SD	Min	Max	Median	IQR
T1DM	376	8.2	1.6	5.5	16.3	7.8	7.1 - 9.0
T2DM	965	8.0	1.7	4.7	15.0	7.8	6.8 - 8.8
Other	37	8.0	2.2	4.4	15.4	7.9	6.7 - 8.6
Don't know	3	8.8	2.8	7.0	12.1	7.4	7.2 - 9.8
Total	1381	8.1	1.7	4.4	16.3	7.8	6.9 - 8.8


















Mean total cholesterol, HDL cholesterol and median triglycerides by diabetes type


Diabetes type		Tota	l cholest	erol				HDL			Triglycerides		
Diabetes type	n	Mean	SD	Min	Max	n	Mean	SD	Min	Max	n	Median	IQR
T1DM	282	4.5	1.0	2.3	9.2	244	1.5	0.4	0.5	3.3	277	0.9	0.7 - 1.4
T2DM	758	4.0	1.1	1.7	10.2	709	1.2	0.4	0.5	3.8	757	1.7	1.2 - 2.4
Other	32	4.4	1.3	2.4	8.6	25	1.3	0.3	0.8	2.0	31	1.3	0.9 - 1.6
Don't know	2	4.8	0.7	4.3	5.3	1	1.3	NA	1.3	1.3	2	1.5	1.5 - 1.5
Total	1074	4.2	1.1	1.7	10.2	979	1.3	0.4	0.5	3.8	1067	1.5	1.0 - 2.1



























Total cholesterol by diabetes type


Dichetes type	<4	4.0 (mmol/	/L)	≥	4.0 (mmol/	L)	Total		
Diabetes type	n	R%	C%	n	R%	C%	n	%	
T1DM	81	28.7	16.7	201	71.3	34.2	282	26.3	
T2DM	394	52.0	81.1	364	48.0	61.9	758	70.6	
Other	11	34.4	2.3	21	65.6	3.6	32	3.0	
Don't know	0	0.0	0.0	2	100.0	0.3	2	0.2	
Total	486	45.3		588	54.7		1074		


















HDL cholesterol by diabetes type


Diabetes type	<′	1.0 (mmol/	/L)	≥	1.0 (mmol/	L)	Total		
Diabetes type	n	R%	C%	n	R%	C%	n	%	
T1DM	15	6.1	6.9	229	93.9	30.1	244	24.9	
T2DM	197	27.8	90.8	512	72.2	67.2	709	72.4	
Other	5	20.0	2.3	20	80.0	2.6	25	2.6	
Don't know	0	0.0	0.0	1	100.0	0.1	1	0.1	
Total	217	22.2		762	77.8		979		


















Triglycerides by diabetes type


_</th <th>2.0 (mmol/</th> <th>L)</th> <th>≥2</th> <th>2.0 (mmol/</th> <th>L)</th> <th>To</th> <th>tal</th>	2.0 (mmol/	L)	≥2	2.0 (mmol/	L)	To	tal	
n	D0/				•	Total		
	R%	C%	n	R%	C%	n	%	
248	89.5	33.6	29	10.5	8.8	277	26.0	
463	61.2	62.7	294	38.8	89.4	757	70.9	
25	80.6	3.4	6	19.4	1.8	31	2.9	
2	100.0	0.3	0	0.0	0.0	2	0.2	
738	69.2		329	30.8		1067		
	248 463 25 2	248 89.5 463 61.2 25 80.6 2 100.0	248 89.5 33.6 463 61.2 62.7 25 80.6 3.4 2 100.0 0.3	248 89.5 33.6 29 463 61.2 62.7 294 25 80.6 3.4 6 2 100.0 0.3 0	248 89.5 33.6 29 10.5 463 61.2 62.7 294 38.8 25 80.6 3.4 6 19.4 2 100.0 0.3 0 0.0	248 89.5 33.6 29 10.5 8.8 463 61.2 62.7 294 38.8 89.4 25 80.6 3.4 6 19.4 1.8 2 100.0 0.3 0 0.0 0.0	248 89.5 33.6 29 10.5 8.8 277 463 61.2 62.7 294 38.8 89.4 757 25 80.6 3.4 6 19.4 1.8 31 2 100.0 0.3 0 0.0 0.0 2	

















Mean LDL cholesterol by diabetes type

Diabetes type			LDL		
Diabetes type	n	Mean	SD	Min	Max
T1DM	249	2.4	0.8	0.5	5.3
T2DM	686	2.0	0.9	0.0	7.0
Other	24	2.2	0.9	0.8	3.6
Don't know	1	2.3	NA	2.3	2.3
Total	960	2.1	0.9	0.0	7.0











LDL cholesterol by diabetes type


Diabetes type	</th <th>2.0 (mmol/</th> <th>/L)</th> <th>≥</th> <th>2.0 (mmol/</th> <th colspan="2">Total</th>	2.0 (mmol/	/L)	≥	2.0 (mmol/	Total		
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	77	30.9	16.2	172	69.1	35.5	249	25.9
T2DM	389	56.7	81.7	297	43.3	61.4	686	71.5
Other	10	41.7	2.1	14	58.3	2.9	24	2.5
Don't know	0	0.0	0.0	1	100.0	0.2	1	0.1
Total	476	49.6		484	50.4		960	


















Albuminuria by diabetes type


Diabetes type	Normal t	Normal to mildly increased		Moderately increased			Severely increased			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	190	84.8	35.3	16	7.1	17.6	18	8.0	18.0	224	30.7
T2DM	335	68.6	62.2	74	15.2	81.3	79	16.2	79.0	488	66.8
Other	12	80.0	2.2	1	6.7	1.1	2	13.3	2.0	15	2.1
Don't know	2	66.7	0.4	0	0.0	0.0	1	33.3	1.0	3	0.4
Total	539	73.8		91	12.5		100	13.7		730	
























eGFR levels by diabetes type


Dichetee tune		eGFR ≥90			eGFR 60 - <90			eGFR 30 - <60		
Diabetes type	n	R%	C%	n	R%	C%	n	R%	C%	
T1DM	63	31.2	44.1	100	49.5	20.8	30	14.9	11.3	
T2DM	76	10.4	53.1	368	50.5	76.5	228	31.3	86.0	
Other	4	14.8	2.8	13	48.1	2.7	7	25.9	2.6	
Don't know	NA	NA	NA	NA	NA	NA	NA	NA	NA	
Total	143	14.9		481	50.2		265	27.7		


Dishetes type	e(GFR 15 - <	30		eGFR <1	Total		
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	5	2.5	10.6	4	2.0	18.2	202	15.4
T2DM	40	5.5	85.1	17	2.3	77.3	729	55.7
Other	2	7.4	4.3	1	3.7	4.5	27	2.1
Don't know	NA	NA	NA	NA	NA	NA	NA	NA
Total	47	4.9		22	2.3		958	


Serum creatinine levels by diabetes type


Diabetes type	<1	<120 (µmol/L)			≥120 - ≤500 (µmol/L)			>500 (µmol/L) (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%	
T1DM	313	92.6	28.0	22	6.5	12.4	3	0.9	21.4	338	25.8	
T2DM	770	82.8	69.0	149	16.0	83.7	11	1.2	78.6	930	71.1	
Other	30	81.1	2.7	7	18.9	3.9	0	0.0	0.0	37	2.8	
Don't know	3	100.0	0.3	0	0.0	0.0	0	0.0	0.0	3	0.2	
Total	1116	85.3		178	13.6		14	1.1		1308		


















Anti-hypertensive therapy use by diabetes type


Dichetes type		Yes			No	Total		
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	144	36.3	15.3	253	63.7	52.4	397	27.8
T2DM	779	78.8	82.6	209	21.2	43.3	988	69.3
Other	19	50.0	2.0	19	50.0	3.9	38	2.7
Don't know	1	33.3	0.1	2	66.7	0.4	3	0.2
Total	943	66.1		483	33.9		1426	


















ACE inhibitor use by diabetes type


Diabataa tuna		Yes			No	Total		
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	73	50.7	19.7	71	49.3	12.4	144	15.3
T2DM	293	37.6	79.0	486	62.4	85.0	779	82.6
Other	5	26.3	1.3	14	73.7	2.4	19	2.0
Don't know	0	0.0	0.0	1	100.0	0.2	1	0.1
Total	371	39.3		572	60.7		943	


















ARB use by diabetes type


Dishetes tune		Yes			No		Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	55	38.2	12.9	89	61.8	17.2	144	15.3
T2DM	359	46.1	84.5	420	53.9	81.1	779	82.6
Other	10	52.6	2.4	9	47.4	1.7	19	2.0
Don't know	1	100.0	0.2	0	0.0	0.0	1	0.1
Total	425	45.1		518	54.9		943	


















Calcium channel blocker use by diabetes type


Diabetes tune		Yes			No		Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	42	29.2	13.0	102	70.8	16.5	144	15.3
T2DM	275	35.3	84.9	504	64.7	81.4	779	82.6
Other	7	36.8	2.2	12	63.2	1.9	19	2.0
Don't know	0	0.0	0.0	1	100.0	0.2	1	0.1
Total	324	34.4		619	65.6		943	


















Thiazide use by diabetes type


Dishetes type		Yes			No	Total		
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	28	19.4	11.3	116	80.6	16.7	144	15.3
T2DM	215	27.6	87.0	564	72.4	81.0	779	82.6
Other	4	21.1	1.6	15	78.9	2.2	19	2.0
Don't know	0	0.0	0.0	1	100.0	0.1	1	0.1
Total	247	26.2		696	73.8		943	


















Beta blocker use by diabetes type


Dichetes type		Yes			No	Total		
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	28	19.4	9.5	116	80.6	17.9	144	15.3
T2DM	259	33.2	88.1	520	66.8	80.1	779	82.6
Other	7	36.8	2.4	12	63.2	1.8	19	2.0
Don't know	0	0.0	0.0	1	100.0	0.2	1	0.1
Total	294	31.2		649	68.8		943	


















Other anti-hypertensive therapy by diabetes type


Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	14	9.7	14.9	130	90.3	15.3	144	15.3
T2DM	78	10.0	83.0	701	90.0	82.6	779	82.6
Other	2	10.5	2.1	17	89.5	2.0	19	2.0
Don't know	0	0.0	0.0	1	100.0	0.1	1	0.1
Total	94	10.0		849	90.0		943	

















Number of anti-hypertensive medications by diabetes type


Dichetee type		1			2			3		≥4	(Not grap	hed)	To	otal
Diabetes type	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	78	19.6	19.3	42	10.6	13.0	18	4.5	10.8	6	12.0	12.0	397	27.8
T2DM	317	32.1	78.5	272	27.5	84.5	147	14.9	88.0	43	4.4	86.0	988	69.3
Other	8	21.1	2.0	8	21.1	2.5	2	5.3	1.2	1	2.6	2.0	38	2.7
Don't know	1	33.3	0.2	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	3	0.2
Total	404	28.3		322	22.6		167	11.7		50	3.5		1426	


^{*}Of patients taking anti-hypertensive therapy



























Lipid modifying therapy by diabetes type


Dishetes tune		Yes			No		To	otal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	173	43.7	18.2	223	56.3	47.2	396	27.8
T2DM	762	77.3	80.1	224	22.7	47.5	986	69.3
Other	15	39.5	1.6	23	60.5	4.9	38	2.7
Don't know	1	33.3	0.1	2	66.7	0.4	3	0.2
Total	951	66.8		472	33.2		1423	

















Statin* use by diabetes type


Diabetes type		Yes			No			ntraindica lot graphe		Total		
	n	R%	C%	n	R%	C%	n	R%	C%	n	%	
T1DM	159	91.9	17.8	13	7.5	27.7	1	0.6	9.1	173	18.2	
T2DM	719	94.4	80.5	33	4.3	70.2	10	1.3	90.9	762	80.1	
Other	14	93.3	1.6	1	6.7	2.1	0	0.0	0.0	15	1.6	
Don't know	1	100.0	0.1	0	0.0	0.0	0	0.0	0.0	1	0.1	
Total	893	93.9		47	4.9		11	1.2		951		


^{*}Of patients taking lipid modifying therapy

















Fibrate* use by diabetes type


Diabetes type		Yes			No			ntraindica lot graphe		To	otal
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	15	8.8	14.4	155	90.6	18.5	1	0.6	33.3	171	18.1
T2DM	86	11.3	82.7	671	88.4	80.0	2	0.3	66.7	759	80.2
Other	3	20.0	2.9	12	80.0	1.4	0	0.0	0.0	15	1.6
Don't know	0	0.0	0.0	1	100.0	0.1	0	0.0	0.0	1	0.1
Total	104	11.0		839	88.7		3	0.3		946	


^{*}Of patients taking lipid modifying therapy

















Ezetimibe* use by diabetes type


Diabetes type		Yes			No			ntraindica Not graphe		To	otal
T1DM	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	28	16.3	21.1	142	82.6	17.5	2	1.2	66.7	172	18.2
T2DM	103	13.6	77.4	655	86.3	80.8	1	0.1	33.3	759	80.2
Other	2	13.3	1.5	13	86.7	1.6	0	0.0	0.0	15	1.6
Don't know	0	0.0	0.0	1	100.0	0.1	0	0.0	0.0	1	0.1
Total	133	14.0		811	85.6		3	0.3		947	


^{*}Of patients taking lipid modifying therapy

















Fish oil* use by diabetes type


Diabetes type		Yes			No			ntraindica Not graphe		To	otal
Γ1DM	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	28	16.3	21.1	142	82.6	17.5	2	1.2	66.7	172	18.2
T2DM	103	13.6	77.4	655	86.3	80.8	1	0.1	33.3	759	80.2
Other	2	13.3	1.5	13	86.7	1.6	0	0.0	0.0	15	1.6
Don't know	0	0.0	0.0	1	100.0	0.1	0	0.0	0.0	1	0.1
Total	133	14.0		811	85.6		3	0.3		947	


^{*}Of patients taking lipid modifying therapy














PCSK9 inhibitor* use by diabetes type


Diabetes tune		Yes			No		Co	ntraindica	ated	To	otal
Diabetes type	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	0	0.0	0.0	170	98.8	18.1	2	1.2	100.0	172	18.2
T2DM	4	0.5	100.0	755	99.5	80.2	0	0.0	0.0	759	80.2
Other	0	0.0	0.0	15	100.0	1.6	0	0.0	0.0	15	1.6
Don't know	0	0.0	0.0	1	100.0	0.1	0	0.0	0.0	1	0.1
Total	4	0.4		941	99.4		2	0.2		947	


^{*}Of patients taking lipid modifying therapy


Antiplatelet therapy use by diabetes type


Diabetes type		Yes			No			ntraindica Not graphe		To	otal
Γ1DM	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	65	16.4	14.7	331	83.6	34.0	0	0.0	NA	396	27.8
T2DM	370	37.5	83.7	609	61.8	62.5	7	0.7	NA	986	69.3
Other	7	18.4	1.6	31	81.6	3.2	0	0.0	NA	38	2.7
Don't know	0	0.0	0.0	3	100.0	0.3	0	0.0	NA	3	0.2
Total	442	31.1		974	68.4		0	0.0		1423	


^{*}Of patients taking aspirin and/or anti-platelet therapy


















Anti-coagulant therapy by diabetes type


Dish stee town		Yes			No		1)	lot graphe	d)	To	otal
Diabetes type	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	20	5.1	14.6	375	94.7	29.3	1	0.3	NA	396	27.8
T2DM	116	11.8	84.7	867	87.9	67.6	3	0.3	NA	986	69.3
Other	1	2.6	0.7	37	97.4	2.9	0	0.0	NA	38	2.7
Don't know	0	0.0	0.0	3	100.0	0.2	0	0.0	NA	3	0.2
Total	137	9.6		1282	90.1		0	0.0		1423	














Diabetic ketoacidosis (last 12 months) by diabetes type

Dishetes type		Yes			No		To	tal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	20	5.0	71.4	377	95.0	27.0	397	27.9
T2DM	7	0.7	25.0	979	99.3	70.1	986	69.2
Other	1	2.6	3.6	37	97.4	2.7	38	2.7
Don't know	0	0.0	0.0	3	100.0	0.2	3	0.2
Total	28	2.0		1396	98.0		1424	

Hyperosmolar hyperglycaemic state (last 12 months) by diabetes type


•			•	, ,			
	Yes			No		To	tal
n	R%	C%	n	R%	C%	n	%
0	0.0	0.0	397	100.0	28.0	397	27.9
5	0.5	83.3	981	99.5	69.2	986	69.2
0	0.0	0.0	38	100.0	2.7	38	2.7
1	33.3	16.7	2	66.7	0.1	3	0.2
6	0.4		1418	99.6		1424	
	n 0 5 0	N Yes 0 0.0 5 0.5 0 0.0 1 33.3	Yes n R% C% 0 0.0 0.0 5 0.5 83.3 0 0.0 0.0 1 33.3 16.7	Yes n R% C% n 0 0.0 0.0 397 5 0.5 83.3 981 0 0.0 0.0 38 1 33.3 16.7 2	Yes No n R% C% n R% 0 0.0 0.0 397 100.0 5 0.5 83.3 981 99.5 0 0.0 0.0 38 100.0 1 33.3 16.7 2 66.7	Yes No n R% C% n R% C% 0 0.0 0.0 397 100.0 28.0 5 0.5 83.3 981 99.5 69.2 0 0.0 0.0 38 100.0 2.7 1 33.3 16.7 2 66.7 0.1	Yes No To n R% C% n R% C% n 0 0.0 0.0 397 100.0 28.0 397 5 0.5 83.3 981 99.5 69.2 986 0 0.0 0.0 38 100.0 2.7 38 1 33.3 16.7 2 66.7 0.1 3


Impaired awareness of hypoglycaemia (last 12 months) by diabetes type


Diabetes type		Yes			No		To	otal
	n	R%	C%	n	R%	C%	n	%
T1DM	43	10.8	69.4	354	89.2	26.0	397	27.9
T2DM	17	1.7	27.4	969	98.3	71.1	986	69.3
Other	2	5.3	3.2	36	94.7	2.6	38	2.7
Don't know	0	0.0	0.0	3	100.0	0.2	3	0.2
Total	62	4.4		1362	95.6		1424	


Severe hypoglycaemia (last 12 months) by diabetes type


Dishetes type		Yes			No	Total		
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	37	9.3	61.7	360	90.7	26.4	397	27.9
T2DM	21	2.1	35.0	964	97.9	70.7	985	69.2
Other	2	5.3	3.3	36	94.7	2.6	38	2.7
Don't know	0	0.0	0.0	3	100.0	0.2	3	0.2
Total	60	4.2		1363	95.8		1423	

















Retinopathy* by diabetes type


Diabetes type		Yes			No			Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%	
T1DM	121	30.6	33.3	275	69.4	25.9	396	27.8	
T2DM	239	24.2	65.8	747	75.8	70.5	986	69.3	
Other	3	7.9	0.8	35	92.1	3.3	38	2.7	
Don't know	0	0.0	0.0	3	100.0	0.3	3	0.2	
Total	363	25.5		1060	74.5		1423		


^{*}Ever reported (either in the last 12 months or prior to the last 12 months)

















Treatment for retinopathy* by diabetes type


Dishetes type	Yes			No			Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	71	17.9	33.3	326	82.1	26.9	397	27.9
T2DM	141	14.3	66.2	845	85.7	69.8	986	69.3
Other	1	2.6	0.5	37	97.4	3.1	38	2.7
Don't know	0	0.0	0.0	3	100.0	0.2	3	0.2
Total	213	15.0		1211	85.0		1424	


^{*}Ever reported (either in the last 12 months or prior to the last 12 months)

















Cataract* by diabetes type


Dichetee tune		Yes			No			Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%	
T1DM	62	15.6	16.7	335	84.4	31.8	397	27.9	
T2DM	301	30.5	81.1	685	69.5	65.1	986	69.3	
Other	8	21.1	2.2	30	78.9	2.8	38	2.7	
Don't know	0	0.0	0.0	3	100.0	0.3	3	0.2	
Total	371	26.1		1053	73.9		1424		


^{*}Ever reported (either in the last 12 months or prior to the last 12 months)

















Blindness* by diabetes type


Dishetes type	Yes			No			Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	9	2.3	28.1	388	97.7	27.9	397	27.9
T2DM	23	2.3	71.9	963	97.7	69.2	986	69.3
Other	0	0.0	0.0	38	100.0	2.7	38	2.7
Don't know	0	0.0	0.0	3	100.0	0.2	3	0.2
Total	32	2.2		1392	97.8		1424	


^{*}Ever reported (either in the last 12 months or prior to the last 12 months)

















Peripheral neuropathy* by diabetes type


Dichetee tune		Yes			No			Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%	
T1DM	68	17.1	23.0	329	82.9	29.2	397	27.9	
T2DM	224	22.7	75.7	762	77.3	67.6	986	69.3	
Other	3	7.9	1.0	35	92.1	3.1	38	2.7	
Don't know	1	33.3	0.3	2	66.7	0.2	3	0.2	
Total	296	20.8		1128	79.2		1424		


^{*}Ever reported (either in the last 12 months or prior to the last 12 months)

















Foot ulceration* by diabetes type


Dishetes type		Yes			No			tal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	34	8.6	25.4	363	91.4	28.1	397	27.9
T2DM	100	10.1	74.6	886	89.9	9.1	986	69.3
Other	0	0.0	0.0	38	100.0	2.9	38	2.7
Don't know	0	0.0	0.0	3	100.0	0.2	3	0.2
Total	134	9.4		1290	90.6		1424	


^{*}Ever reported (either in the last 12 months or prior to the last 12 months)

















Lower limb amputation* by diabetes type


Dishetes type		Yes			No			Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%	
T1DM	17	4.3	23.9	380	95.7	28.1	397	27.9	
T2DM	54	5.5	76.1	932	94.5	9.6	986	69.3	
Other	0	0.0	0.0	38	100.0	2.8	38	2.7	
Don't know	0	0.0	0.0	3	100.0	0.2	3	0.2	
Total	71	5.0		1353	95.0		1424		


^{*}Ever reported (either in the last 12 months or prior to the last 12 months)

















Depression* by diabetes type


Dishetes type	Yes			No			Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	100	25.2	27.6	297	74.8	28.0	397	27.9
T2DM	249	25.3	68.8	736	74.7	7.6	985	69.2
Other	12	31.6	3.3	26	68.4	2.5	38	2.7
Don't know	1	33.3	0.3	2	66.7	0.2	3	0.2
Total	362	25.4		1061	74.6		1423	


^{*}Ever reported (either in the last 12 months or prior to the last 12 months)

















Anxiety* by diabetes type


Diabetes type		Yes			No			Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%	
T1DM	94	23.7	33.7	303	76.3	26.5	397	27.9	
T2DM	177	18.0	63.4	809	82.0	8.3	986	69.3	
Other	7	18.4	2.5	31	81.6	2.7	38	2.7	
Don't know	1	33.3	0.4	2	66.7	0.2	3	0.2	
Total	279	19.6		1145	80.4		1424		


^{*}Ever reported (either in the last 12 months or prior to the last 12 months)














Dementia* by diabetes type

Dichetee type		Yes			No			Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%	
T1DM	1	0.3	5.3	396	99.7	28.2	397	27.9	
T2DM	18	1.8	94.7	968	98.2	10.0	986	69.3	
Other	0	0.0	0.0	38	100.0	2.7	38	2.7	
Don't know	0	0.0	0.0	3	100.0	0.2	3	0.2	
Total	19	1.3		1405	98.7		1424		

^{*}Ever reported (either in the last 12 months or prior to the last 12 months)

Malignancy* by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	12	3.0	9.2	385	97.0	29.8	397	27.9
T2DM	111	11.3	85.4	875	88.7	9.0	986	69.3
Other	7	18.4	5.4	31	81.6	2.4	38	2.7
Don't know	0	0.0	0.0	3	100.0	0.2	3	0.2
Total	130	9.1		1294	90.9		1424	

^{*}Ever reported (either in the last 12 months or prior to the last 12 months)


Tested positive to COVID-19* by diabetes type


		•		•	•	•			
Diabetes type	Yes			No			Total		
	n	R%	C%	n	R%	C%	n	%	
T1DM	215	55.6	31.3	172	44.4	24.2	387	27.2	
T2DM	447	46.0	65.1	525	54.0	5.6	972	68.3	
Other	22	59.5	3.2	15	40.5	2.1	37	2.6	
Don't know	3	100.0	0.4	0	0.0	0.0	3	0.2	
Total	687	49.1		712	50.9		1399		


^{*}Ever reported (either in the last 12 months or prior to the last 12 months)


Liver disease by diabetes type


Diabetes type —		Mild			Moderate			Nil (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%	
T1DM	29	7.4	13.7	14	3.6	20.9	351	89.1	30.8	394	27.8	
T2DM	180	18.3	85.3	46	4.7	68.7	756	77.0	66.4	982	69.3	
Other	2	5.3	0.9	7	18.4	10.4	29	76.3	2.5	38	2.7	
Don't know	0	0.0	0.0	0	0.0	0.0	3	100.0	0.3	3	0.2	
Total	211	14.9		67	4.7		1139	80.4		1417		

















Number of complications* by diabetes type


Diabetes type		0			≥1			Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%	
T1DM	193	48.6	30.3	204	51.4	25.8	397	27.8	
T2DM	423	42.8	66.5	565	57.2	71.5	988	69.3	
Other	19	50.0	3.0	19	50.0	2.4	38	2.7	
Don't know	1	33.3	0.2	2	66.7	0.3	3	0.2	
Total	636	44.6		790	55.4		1426		


^{*}Ever reported (percentage of patients with a diagnosis/detection either in the last 12 months or prior to the last 12 months)

















Number of cardiovascular complications* by diabetes type


Diabetes type		0			≥1			tal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	365	91.9	31.5	32	8.1	11.9	397	27.8
T2DM	755	76.4	65.3	233	23.6	86.6	988	69.3
Other	34	89.5	2.9	4	10.5	1.5	38	2.7
Don't know	3	100.0	0.3	0	0.0	0.0	3	0.2
Total	1157	81.1		269	18.9		1426	


^{*}Ever reported (percentage of patients with a diagnosis/detection either in the last 12 months or prior to the last 12 months)

















Number of cardiovascular complications* (current smokers) by diabetes type


Diabetes type		0			≥1			otal
	n	R%	C%	n	R%	C%	n	%
T1DM	40	90.9	37.0	4	9.1	25.0	44	35.5
T2DM	64	84.2	59.3	12	15.8	75.0	76	61.3
Other	4	100.0	3.7	0	0.0	0.0	4	3.2
Don't know	NA	NA	NA	NA	NA	NA	NA	NA
Total	108	87.1		16	12.9		124	


^{*}Ever reported (percentage of patients with a diagnosis/detection either in the last 12 months or prior to the last 12 months)

















Number of cardiovascular complications* (past smokers) by diabetes type


Diabetes type		0			≥1			Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%	
T1DM	58	85.3	25.0	10	14.7	10.4	68	20.7	
T2DM	163	66.3	70.3	83	33.7	86.5	246	75.0	
Other	9	75.0	3.9	3	25.0	3.1	12	3.7	
Don't know	2	100.0	0.9	0	0.0	0.0	2	0.6	
Total	232	70.7		96	29.3		328		


^{*}Ever reported (percentage of patients with a diagnosis/detection either in the last 12 months or prior to the last 12 months)

















Number of cardiovascular complications* (never smoked) by diabetes type


Dishetes type		0			≥1		To	tal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	162	95.3	33.8	8	4.7	9.5	170	30.2
T2DM	304	80.0	63.5	76	20.0	90.5	380	67.5
Other	12	100.0	2.5	0	0.0	0.0	12	2.1
Don't know	1	100.0	0.2	0	0.0	0.0	1	0.2
Total	479	85.1		84	14.9		563	


^{*}Ever reported (percentage of patients with a diagnosis/detection either in the last 12 months or prior to the last 12 months)














Screened for diabetes distress (last 12 months) by diabetes type

Diabetes type		Yes			No			Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%	
T1DM	20	5.1	29.9	375	94.9	27.8	395	27.9	
T2DM	44	4.5	65.7	938	95.5	69.4	982	69.3	
Other	3	7.9	4.5	35	92.1	2.6	38	2.7	
Don't know	0	0.0	0.0	3	100.0	0.2	3	0.2	
Total	67	4.7		1351	95.3		1418		

Screened for depression (last 12 months) by diabetes type


Diabetes type		Yes			No			Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%	
T1DM	40	10.1	28.0	355	89.9	27.8	395	27.9	
T2DM	95	9.7	66.4	887	90.3	69.6	982	69.3	
Other	8	21.1	5.6	30	78.9	2.4	38	2.7	
Don't know	0	0.0	0.0	3	100.0	0.2	3	0.2	
Total	143	10.1		1275	89.9		1418		


Screened for anxiety (last 12 months) by diabetes type


Diabetes type		Yes			No			otal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	36	9.1	29.0	359	90.9	27.7	395	27.9
T2DM	80	8.1	64.5	902	91.9	69.7	982	69.3
Other	8	21.1	6.5	30	78.9	2.3	38	2.7
Don't know	0	0.0	0.0	3	100.0	0.2	3	0.2
Total	124	8.7		1294	91.3		1418	


COVID-19 vaccination (last 6 months) by diabetes type


Diabetes type		Yes		No			Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	92	30.1	21.6	214	69.9	32.7	306	28.3
T2DM	322	43.5	75.8	419	56.5	64.0	741	68.6
Other	11	36.7	2.6	19	63.3	2.9	30	2.8
Don't know	0	0.0	0.0	3	100.0	0.5	3	0.3
Total	425	39.4		655	60.6		1080	


















Flu vaccination (last 12 months) by diabetes type


Diabetes type		Yes		No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	193	63.3	25.8	112	36.7	33.7	305	28.2
T2DM	533	71.8	71.3	209	28.2	63.0	742	68.7
Other	20	66.7	2.7	10	33.3	3.0	30	2.8
Don't know	2	66.7	0.3	1	33.3	0.3	3	0.3
Total	748	69.3		332	30.7		1080	


















Pneumococcal vaccination (up to date) by diabetes type


Diabetes type		Yes			No			Unsure		To	otal
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	55	18.1	20.6	107	35.2	30.2	142	46.7	31.3	304	28.3
T2DM	199	27.0	74.5	234	31.7	66.1	305	41.3	67.2	738	68.7
Other	12	40.0	4.5	11	36.7	3.1	7	23.3	1.5	30	2.8
Don't know	1	33.3	0.4	2	66.7	0.6	0	0.0	0.0	3	0.3
Total	267	24.8		354	32.9		454	42.2		1075	


















Attended endocrinologist by diabetes type


Diabetes type		Yes		No	Total			
	n	R%	C%	n	R%	C%	n	%
T1DM	255	83.3	35.9	51	16.7	13.7	306	28.3
T2DM	430	57.8	60.6	314	42.2	84.2	744	68.7
Other	22	73.3	3.1	8	26.7	2.1	30	2.8
Don't know	3	100.0	0.4	0	0.0	0.0	3	0.3
Total	710	65.6		373	34.4		1083	


















Attended diabetes educator/nurse practitioner by diabetes type


Diabetes type		Yes		No	Total			
	n	R%	C%	n	R%	C%	n	%
T1DM	244	79.5	34.0	63	20.5	17.2	307	28.3
T2DM	450	60.4	62.7	295	39.6	80.4	745	68.7
Other	21	70.0	2.9	9	30.0	2.5	30	2.8
Don't know	3	100.0	0.4	0	0.0	0.0	3	0.3
Total	718	66.2		367	33.8		1085	


















Attended dietitian by diabetes type


Diabetes type		Yes		No	Total			
	n	R%	C%	n	R%	C%	n	%
T1DM	104	34.0	31.2	202	66.0	26.9	306	28.3
T2DM	214	28.8	64.3	530	71.2	70.7	744	68.7
Other	13	43.3	3.9	17	56.7	2.3	30	2.8
Don't know	2	66.7	0.6	1	33.3	0.1	3	0.3
Total	333	30.7		750	69.3		1083	


















Attended podiatrist by diabetes type


Diabetes type		Yes		No	Total			
	n	R%	C%	n	R%	C%	n	%
T1DM	145	47.1	22.9	163	52.9	36.2	308	28.4
T2DM	475	64.0	75.0	267	36.0	59.3	742	68.5
Other	12	40.0	1.9	18	60.0	4.0	30	2.8
Don't know	1	33.3	0.2	2	66.7	0.4	3	0.3
Total	633	58.4		450	41.6		1083	


















Attended ophthalmologist by diabetes type


Diabetes type		Yes			No	Total		
	n	R%	C%	n	R%	C%	n	%
T1DM	108	35.5	26.3	196	64.5	29.7	304	28.4
T2DM	295	40.1	71.8	440	59.9	66.8	735	68.7
Other	8	27.6	1.9	21	72.4	3.2	29	2.7
Don't know	0	0.0	0.0	2	100.0	0.3	2	0.2
Total	411	38.4		659	61.6		1070	


















Attended optometrist by diabetes type


Dichetes type		Yes			No		Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	218	71.2	27.6	88	28.8	30.4	306	28.4
T2DM	550	74.4	69.7	189	25.6	65.4	739	68.6
Other	19	63.3	2.4	11	36.7	3.8	30	2.8
Don't know	2	66.7	0.3	1	33.3	0.3	3	0.3
Total	789	73.2		289	26.8		1078	


















Attended psychologist/psychiatrist by diabetes type


Diabataa tuna		Yes			No		Total	
Г2DM	n	R%	C%	n	R%	C%	n	%
T1DM	49	16.0	38.0	257	84.0	27.1	306	28.4
T2DM	72	9.7	55.8	668	90.3	70.3	740	68.6
Other	7	23.3	5.4	23	76.7	2.4	30	2.8
Don't know	1	33.3	0.8	2	66.7	0.2	3	0.3
Total	129	12.0		950	88.0		1079	

















Attended social worker by diabetes type


Dichetee type		Yes			No		Total	
Diabetes type	n	R%	C%	n	R%	C%	n 305 738 30 3	%
T1DM	15	4.9	19.5	290	95.1	29.0	305	28.3
T2DM	58	7.9	75.3	680	92.1	68.1	738	68.6
Other	3	10.0	3.9	27	90.0	2.7	30	2.8
Don't know	1	33.3	1.3	2	66.7	0.2	3	0.3
Total	77	7.2		999	92.8		1076	


















Attended dentist by diabetes type


Dichetes type		No			Total			
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	168	54.7	34.6	139	45.3	23.6	307	28.5
T2DM	304	41.3	62.6	432	58.7	73.2	736	68.4
Other	12	40.0	2.5	18	60.0	3.1	30	2.8
Don't know	2	66.7	0.4	1	33.3	0.2	3	0.3
Total	486	45.2		590	54.8		1076	


















Attended exercise physiologist/physiotherapist by diabetes type


Diabataa tuna		Yes		No			Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	63	20.5	26.9	244	79.5	28.7	307	28.3
T2DM	163	21.9	69.7	581	78.1	68.4	744	68.6
Other	7	23.3	3.0	23	76.7	2.7	30	2.8
Don't know	1	33.3	0.4	2	66.7	0.2	3	0.3
Total	234	21.6		850	78.4		1084	














Needed an ambulance by diabetes type

Dichetee type		Yes			No		Total	
Diabetes type	n	R%	C%	n	R%	C%	n 307 745 30 3	%
T1DM	28	9.1	46.7	279	90.9	27.2	307	28.3
T2DM	29	3.9	48.3	716	96.1	69.9	745	68.7
Other	2	6.7	3.3	28	93.3	2.7	30	2.8
Don't know	1	33.3	1.7	2	66.7	0.2	3	0.3
Total	60	5.5		1025	94.5		1085	

Attended the emergency department by diabetes type


Diabetes type		Yes		No	Total			
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	38	12.4	40.9	268	87.6	27.1	306	28.2
T2DM	51	6.9	54.8	692	93.1	70.0	743	68.5
Other	3	10.0	3.2	27	90.0	2.7	30	2.8
Don't know	1	33.3	1.1	2	66.7	0.2	3	0.3
Total	93	8.6		989	91.4		1082	


Forget to take medications by diabetes type


Dishetes tune		Yes			No		Total	
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	58	19.0	31.4	248	81.0	27.6	306	28.2
T2DM	119	16.0	64.3	624	84.0	69.6	743	68.5
Other	8	26.7	4.3	22	73.3	2.5	30	2.8
Don't know	0	0.0	0.0	3	100.0	0.3	3	0.3
Total	185	17.1		897	82.9		1082	


Feet checked by health professional (last 12 months) by diabetes type


Dichetee tune		Yes			No		Total	
Diabetes type	n	R%	C%	n	R%	C%	n 305 746 30	%
T1DM	178	58.4	24.2	127	41.6	36.4	305	28.3
T2DM	540	72.4	73.5	206	27.6	59.0	746	69.3
Other	15	50.0	2.0	15	50.0	4.3	30	2.8
Don't know	2	66.7	0.3	1	33.3	0.3	3	0.3
Total	735	67.8		349	32.2		1084	


















Self feet check by diabetes type


Diabetes type Daily			Weekly				Monthly arely/Never					Total		
Diabetes type	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	98	32.7	81.7	79	26.3	18.4	47	15.7	42.3	76	25.3	21.2	300	29.4
T2DM	266	36.6	221.7	183	25.2	42.6	97	13.3	87.4	181	24.9	50.4	727	71.3
Other	7	24.1	5.8	7	24.1	1.6	3	10.3	2.7	12	41.4	3.3	29	2.8
Don't know	1	33.3	0.8	1	33.3	0.2	0	0.0	0.0	1	33.3	0.3	3	0.3
Total	120	11.8		430	42.2		111	10.9		359	35.2		1020	




































Diet - Know what foods are best to eat by diabetes type

Dichetes tune		Yes			No		Total	
Diabetes type	n	R%	C%	n	R%	C%	n 306 743 29	%
T1DM	291	95.1	28.8	15	4.9	20.8	306	28.4
T2DM	688	92.6	68.2	55	7.4	76.4	743	69.1
Other	27	93.1	2.7	2	6.9	2.8	29	2.7
Don't know	3	100.0	0.3	0	0.0	0.0	3	0.3
Total	1009	93.3		72	6.7		1081	


















Diet - Enough time to prepare healthy meals by diabetes type


Dishetes tune		Yes			No			tal
Diabetes type	n	R%	C%	n	R%	C%	n 307 741	%
T1DM	251	81.8	27.5	56	18.2	33.7	307	28.5
T2DM	635	85.7	69.5	106	14.3	63.9	741	68.9
Other	25	86.2	2.7	4	13.8	2.4	29	2.7
Don't know	3	100.0	0.3	0	0.0	0.0	3	0.3
Total	914	84.6		166	15.4		1080	


















(Adapted) Diet - Does not cost too much to eat healthy meals by diabetes type


Dishetes tune		Yes			No		To	tal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	188	61.2	27.3	119	38.8	30.7	307	28.5
T2DM	483	65.4	70.1	256	34.6	66.1	739	68.7
Other	15	55.6	2.2	12	44.4	3.1	27	2.5
Don't know	3	100.0	0.4	0	0.0	0.0	3	0.3
Total	689	64.0		387	36.0		1076	














(T1DM) Diet - Not hard to count carbs/weigh food


Dishetes type		Yes			No		To	tal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	156	53.6	NA	135	46.4	NA	291	27.0


X-axis: All sites (Descending order)


Physical activity* by diabetes type


Diabetes type	≥1	50 mins/w	eek	<1	50 mins/w	eek	R	arely/Nev	er	To	otal
Diabetes type	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	145	47.4	40.4	98	32.0	27.6	63	20.6	17.1	306	28.3
T2DM	204	27.4	56.8	244	32.8	68.7	296	39.8	80.2	744	68.7
Other	8	26.7	2.2	12	40.0	3.4	10	33.3	2.7	30	2.8
Don't know	2	66.7	0.6	1	33.3	0.3	0	0.0	0.0	3	0.3
Total	359	33.1		355	32.8		369	34.1		1083	


^{*}Moderate or vigorous physical activity



























Muscle strengthening exercise by diabetes type


Dishetes type		Yes			No		To	otal
Diabetes type	n	R%	C%	n	R%	C%	n	%
T1DM	137	44.9	37.6	168	55.1	23.5	305	28.3
T2DM	216	29.1	59.3	525	70.9	73.4	741	68.7
Other	10	33.3	2.7	20	66.7	2.8	30	2.8
Don't know	1	33.3	0.3	2	66.7	0.3	3	0.3
Total	364	33.7		715	66.3		1079	














POST DATA COLLECTON QUESTIONNAIRE RESULTS

At the end of the data collection period, we disseminated a post data collection questionnaire to staff at participating sites. Overall, we received feedback from 21 respondents, which may have included multiple staff from a site. The results in Table 3 highlight that there was a general approval of the 'Process' including the information provided, data definitions form and overall format. Respondents from sites who undertook web-based data collections were slightly more satisfied than respondents from sites who undertook paper-based data collections, with the exception of resource documents.

TABLE 3. POST DATA COLLECTION QUESTIONNAIRE RESULTS BY DATA COLLECTION METHOD

	Likert Scale:	1 = Poor, 3 = Midpoint, 5 = Goo	d (Mean + SD)
Questionnaire category	All (n=21)	Paper-based (n=14)	REDCap (n=7)
Resource documents	4.2 ± 0.7	4.3 ± 0.9	4.0 ± 0.0
Data definitions document	4.1 ± 0.7	4.1 ± 0.9	4.4 ± 0.0
Format (layout of data items)	3.5 ± 0.8	3.4 ± 0.9	3.7 ± 0.5
Ease of form completion	3.3 ± 1.2	3.1 ± 1.2	3.9 ± 0.9
Time to complete the form	2.8 ± 1.2	2.6 ± 1.3	3.1 ± 0.9

REFERENCES

- 1. Bonney M, Harris M, Priddin D. National Divisions Diabetes Program: Recommended GP Subset of the NDOQRIN Dataset and Alternate Fields from which NDOQRIN Fields can Subsequently be Derived. 1999.
- 2. NSW Department of Health. Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus v1.3, 1996.
- National Board of Health and Welfare. Quality and efficiency of diabetes care in Sweden: National performance assessment 2011. Stockholm, Sweden: NBHW; 2011. [Available from: https://silo.tips/download/quality-and-efficiency-of-diabetes-care-in-sweden-national-performance-assessmen].
- 4. National Institute for Health and Care Excellence (UK). Quality and Outcomes Framework Indicators: Diabetes Mellitus. NICE, https://www.nice.org.uk/standards-and-indicators/qofindicators?categories=&page=1 (accessed 7 December 2023).
- 5. Fleming BB, Greenfield S, Engelgau MM, Pogach LM, Clauser SB, Parrott MA. The Diabetes Quality Improvement Project: moving science into health policy to gain an edge on the diabetes epidemic. Diabetes Care. 2001;24(10):1815-20.
- 6. Danek E, Earnest A, Zoungas S. Advancing the Quality of Diabetes Care through Audit and Feedback: Literature Review. Monash University, School of Public Health and Preventive Medicine, May 2017.
- 7. National Diabetes Services Scheme. Australian Type 2 Diabetes Glycaemic Management Algorithm. https://www.diabetessociety.com.au/guideline/australian-type-2-diabetes-glycaemic-management-algorithm-august-2022/ (accessed 2 December 2023)

ADCQR COMMITTEES

ADCQR Scientific Advisory Committee Membership

Member name	Role title and organisation	Contribution
Professor Sophia Zoungas (Chair)	Head, School of Public Health and Preventive Medicine, Monash University and Clinical Endocrinologist, Alfred Health and Monash Health, Melbourne [VIC]	Registry Lead and Data Custodian
Associate Professor Sofianos Andikopoulos	Chief Executive Officer, Australian Diabetes Society [NSW]	National Peak Body Representative
Ms Taryn Black	Chief Strategy Officer, Diabetes Australia [QLD]	National Peak Body Representative
Associate Professor Wendy Davis	Epidemiologist and Applied Biostatistician, The University of Western Australia [WA]	Data/Science Expert
Professor Barbora de Courten OAM	Deputy Dean and Distinguished Professor of Medicine, School of Health & Biomedicine, RMIT University and Specialist Physician, Monash Health [VIC]	Clinical Representative
Dr Gary Deed	General Practitioner and Medical Director, Mediwell Medical Clinic [QLD]	Primary Health Sector Representative
Professor Jeff Flack	Conjoint Professor, School of Medicine, Western Sydney University and Senior Staff Specialist Endocrinologist and Head, Department of Diabetes & Endocrinology and Director, Diabetes Centre, Bankstown- Lidcombe Hospital [NSW]	Clinical Representative
Professor Jenny Gunton	Head, Centre for Diabetes, Obesity and Endocrinology Research and Head, Westmead Institute for Medical Research and Clinical Endocrinologist / Diabetologist, Westmead Hospital [NSW]	Clinical Representative
Mr Trevor Jones	Person living with Type 2 Diabetes [WA]	Consumer Representative
Dr Konrad Kangru	General Practitioner, Whitsunday Doctors Service [QLD]	Primary Health Sector Representative
Associate Professor Odette Pearson	Co-Lead Aboriginal Health Equity Theme, South Australian Health & Medical Research Institute [SA]	Aboriginal and Torres Strait Islander Representative and Data/Science Expert
Ms Megan Phelan	Policy Officer, Clinical Quality Registry Section, Health Modelling, Partnerships and Evaluation Branch, Health Economics and Research Division, Australian Government Department of Health and Aged Care [ACT]	Australian Government Department of Health and Aged Care Representative
Ms Sally Rayner	Director, Clinical Quality Registry Section, Health Modelling, Partnerships and Evaluation Branch, Health Economics and Research Division, Australian Government Department of Health and Aged Care [ACT]	Australian Government Department of Health and Aged Care Representative
Professor Jane Speight	Chair, Behavioural and Social Research in Diabetes and Foundation Director, The Australian Centre for Behavioural Research in Diabetes [VIC]	Data/Science Expert
Ms Natalie Wischer OAM	Chief Executive Officer, National Association of Diabetes Centres [VIC]	National Peak Body Representative

ADCQR Project Executive

Name	Role
Professor Sophia Zoungas	Project Lead
Ms Dimitra Giannopoulos	Project Manager
Professor Susannah Ahern	Technical Advisor
Professor Arul Earnest	Senior Biostatistician
Dr Ella Zomer	Research Lead
Dr Ahmad Reza Pourghaderi	Senior Data Scientist
Dr Hossein Nejati	Senior Data Manager/Analyst
Dr Anthony Pease	Clinician Advisor
Dr Matthew Quigley	Quality Improvement Advisor
Ms Trieu-Anh Truong	Data Manager
Ms Mahima Choudhary	Research Support Officer
Ms Kara Kotsovolos	Administrative Officer

APPENDICES



Australian Diabetes Clinical Quality Registry ADCQR Clinical Data Collection Form

SI	ITI	E S	S1	ГА	FI	FΙ	F	O	RI	V	
_											

Page 1 of 3

1/942
Patient ID Site ID Staff Initials (optional)
How was the consultation conducted? In person Video Phone Participant information sheet given
Section 1. Patient Demographics
1.1 Date of birth
1.3 Date of visit
1.8 Main language spoken at home 1.9 DVA Yes No
1.10 Country of birth 1.11 Residential postcode
Section 2. Diabetes Type & Management
2.1 Date of diagnosis
2.3 Self-monitoring None None Self-monitoring None None None No Unsure of recommended?
(Select all that apply) Finger pricking 2.3.2 How many times a day?
Continuous Glucose Monitoring—2.3.3 Was the sensor worn for ≥ 14 days in the last 3 months?
Flash Glucose Monitoring — Yes — No
<u>if YES</u> , percentage of time sensor was active $\boxed{}$ <70% $\boxed{}$ \geq 70%
2.4 Diet only Metformin SCLT2 inhibitor GLP1/GIP aganist
Glycaemic Glycaemic Glycaemic Glycaemic
Management DPP4 inhibitor Sulphonylurea Thiazolidinedione Acarbose
method
2.4.2 Insulin mode ☐ Basal ☐ Pre-mixed insulin ☐ CSII Automated → ☐ Hybrid closed loop system
(Select all that apply) Basal bolus Pump ————————————————————————————————————
Section 3. Weight & Height (Measured in clinic or self-reported)
3.1 Weight kg 3.2 Height m
Section 4. Blood Pressure
4.1 Blood pressure / mmHg → 4.1.1 Measured in clinic OR Self-reported
4.2 Anti-hypertensive treatment
Section 5. Blood Glucose Control & Renal Function (Most recent in last 12 months)
5.1 HbA1c Result
5.2 eGFR mL/min per 1.73m ² OR Not tested 5.3 Serum creatinine µmol/L OR Not tested
5.4a Urinary albumin mg/L OR Not tested 5.4b Urinary protein mg/L OR Not tested OR Not tested
Section 6. Medications & Lipids
Yes No Contraindicated Yes No
6.1 Aspirin
6.2 Other anti-platelets <u>if YES</u> → Complete below: Not tested
6.3 Anti-coagulants 6.5.1 Total Cholesterol mmol/L OR
6.4 Lipid modifying Rx
if YES →6.4.1 Statin
6.4.2 Fibrate 6.5.3 HDL mmol/L OR
6.4.3 Ezetimibe
6.4.3 Ezetimbe 6.5.4 Triglycerides 6.5.4 Triglycerides 6.4.4 Fish oil



Australian Diabetes Clinical Quality Registry

L	"	VI I		U	1
Pa	ae	2	of	3	

	ADCQR Clir	nical Dat	a Collection Fol	rm		Page 2	of 3	·
					_	٦		
Patient ID			Site ID					
Section 7. Diabetes Related E	ve & Foot Complic	ations						
Cootion 1. Biabotoo Roiatoa E	<u> </u>		ast 12 months	Diagnose	d previous	s to the last	12 mont	h <u>s</u>
		Yes	No		Yes	No		_
7.1 Retinopathy		Ц						
7.2 Treatment for retinopathy								
7.3 Right or left cataract		Ш						
7.4 Blindness								
7.5 Peripheral neuropathy								
7.6 Foot ulceration						Ш		
7.7 Lower limb amputation								
<u>if YES</u> (Select all t	that apply) \rightarrow 7.7.1 \square !	Minor 🔲 N	Major	7.7.2	Minor _] Major		
Section 8. Other Complication	s/Events/Comorbio	dities		1				
		ed in the l	ast 12 months	Diagnose		s to the last	12 month	h <u>s</u>
		Yes	No		Yes	No		
8.1 Cerebral stroke						H		
8.2 Myocardial infarction								
8.3 CABG/Angioplasty						Ļ.		
8.4 Congestive cardiac failure								
8.5 Peripheral vascular disease								
8.6 End stage kidney disease								
8.7 Sexual dysfunction								
8.8 Dementia								
8.9 Depression								
8.10 Anxiety								
8.11 Malignancy (exclude non-melan	otic skin cancers)							
8.12 Diabetic ketoacidosis								
8.13 Hyperosmolar hyperglycaem	ic state	$\overline{\Box}$						
8.14 Impaired awareness of hypo								
8.15 Severe hypoglycaemia								
	3 1-2 3-5 T	>5						
<u>if YES</u> → 8.15.1 No. of episodes								
8.16 Liver disease Mild	Moderate/Severe		t applicable					
		Last 12 r	months	Prev	ious to th	e last 12 mc	<u>onths</u>	
8.17 Has the patient tested positi	ve to COVID-19?	Yes	No		Yes	No		
<u>if YES</u> \rightarrow 8.17.1 Was the path	ent hospitalised?	Yes	No	8.17.2	Yes	No No		
Section 9. Mental Health Screen	ning (if not previously o	liagnosed)						
9.1 Has the patient been screened (e.g. PAID, DDS)	for diabetes distres	s in the la	ast 12 months us	ing a valid	ated mea	sure?	Yes	No
9.2 Has the patient been screened (e.g. PHQ_9)	l for depression in th	ne last 12	months using a	validated n	neasure?		Yes	No No
9.3 Has the patient been screened (e.g. GAD-7)	l for anxiety in the la	st 12 mor	nths using a valid	lated meas	ure?		Yes	No
Please indicate whether the	patient health and	well-bei	ng questionnai	re will be	complet	ed?		
Yes → Please complete the	e questionnaire on page	3.						

 $\ensuremath{\text{No}} \ensuremath{\longrightarrow}$ Thank you for completing the ADCQR data collection form.



PATIENT HEALTH & WELL-BEING QUESTIONNAIRE Australian Diabetes Clinical Quality Registry

PATIENT FORM

Page 3 of 3

17942					_											
Patient ID													Site ID			
(OFF	ICE	USE	ONL	Y - S	Site s	taff t	to co	mple	te Pa	atient	ID)					

(c	
Please answer all questions by marking the appropriate box	Cross box like this:
Section 1. Smoking & Vaccination Status	
1.1 Do you currently smoke tobacco? ☐ Yes ☐ No → 1.1.1 <u>If NO</u> , did you previously small [i.e. cigarettes/cigars/e-cigarettes(vaping)]	noke tobacco? Yes No
1.2 Have you had a COVID-19 vaccination in the last 6 months?	Yes No
1.3 Have you had a flu (influenza) vaccination in the last 12 months?	Yes No
1.4 Are you up to date with your pneumococcal vaccination?	Yes No Unsure
Section 2. Health Professional Attendances	
2.1 Have you seen an Endocrinologist in the last 12 months?	Yes No
2.2 Have you seen a Diabetes Educator/Nurse Practitioner in the last 12 months?	Yes No
2.3 Have you seen a Dietitian in the last 12 months?	Yes No
2.4 Have you seen a Podiatrist in the last 12 months?	Yes No
2.5 Have you seen an Ophthalmologist in the last 12 months?	Yes No
2.6 Have you seen an Optometrist in the last 12 months?	Yes No
2.7 Have you seen a Psychologist/Psychiatrist in the last 12 months?	Yes No
2.8 Have you seen a Social Worker in the last 12 months?	Yes No
2.9 Have you seen a Dentist in the last 12 months?	Yes No
2.10 Have you seen an Exercise Physiologist/Physiotherapist in the last 12 months?	Yes No
2.11 Have you needed an Ambulance for your diabetes in the last 12 months?	Yes No
2.12 Have you attended the Emergency Department for your diabetes in the last 12 mo	nths? Yes No
Section 3. Medication Use	
3.1 Sometimes people do not take their medications as recommended. Has this happened to you in the last 2 weeks?	ned Yes No
3.1.1 → <u>If YES,</u> how n	nany times?
Section 4. Foot Care	
4.1 Have you had your feet checked by a health professional in the last 12 months?	Yes No
4.2 How often do you self check your feet?	/ Rarely/Never
Section 5. Nutrition/Diet Management	
5.1 Do you know what foods are best to eat?	Yes No
5.2 Do you have enough time to prepare healthy meals?	Yes No
5.3 Does it cost too much to eat healthy meals?	Yes No
5.4 If you have type 1 diabetes - Do you find it hard to count carbs/weigh food?	Yes No
Section 6. Physical Activity	
6.1 How many minutes per week of moderate or vigorous 150 mins/week or more	
intensity physical activity do you usually do? Less than 150 mins/week	
(e.g. brisk walking, lawrinowing, swimming, or more vigorous —	or vigorous physical activity
6.2 Do you do any muscle strengthening exercise in a usual week?	☐ Yes ☐ No
(e.g. lifting weights or household tasks that involve lifting, carrying or digging)	☐ 1 G2 ☐ 1NO
	_

THANK YOU FOR COMPLETING THE QUESTIONNAIRE. PLEASE RETURN TO STAFF.



Identifiers	
Patient ID	Compulsory field. Enter identifier such as record number or use the following
	nomenclature: site ID, the first 2 letters of the first name, and the first 2 letters of
	the surname (e.g. NNNFFSS) to enable you to check your records if there is a query
	from the ADCQR regarding the data.
Site ID	Unique site identifier (assigned by the ADCQR Secretariat).
Staff initials (optional)	Site staff initials.
Visit conduct	Record if the consultation was conducted in person , by video or by phone .
Participant information	Mark if the patient was provided with the participant information sheet.
sheet given	mann man patient mas promasa man and paranopant mormation encode
Section 1. Patient Demograph	hics
Date of birth	Record the patient's date of birth as DD/MM/YYYY .
Sex	Mark Male or Female or Other to indicate the person's recorded sex at birth.
Currently pregnant	If sex is female, mark Yes or No to indicate if the patient is currently pregnant.
Date of visit	Record the date the patient attended as DD/MM/YYYY .
Initial visit	Mark Yes or No to indicate if this is an initial visit assessment at this site.
Aboriginal/Torres Strait	Mark Yes or No to indicate it this is an initial visit assessment at this site. Mark Yes or No to indicate Aboriginal/Torres Strait Islander background.
Islander	ivial k res or NO to indicate Aboriginal/Torres strait islander background.
Main language spoken at	Record the patient's main language spoken at home.
home	
Interpreter required	Mark Yes or No to indicate if the patient requires an interpreter.
Residential postcode	Record the patient's residential postcode.
NDSS registrant	Mark Yes or No to indicate if the patient is registered on the National Diabetes
	Services Scheme (NDSS).
Country of birth	Record the patient's country of birth.
DVA	Mark Yes or No to indicate if the patient's medical care charges are met by the
	Department of Veterans' Affairs (DVA).
Section 2. Diabetes Type & M	
Date of diagnosis	Record first diagnostic blood glucose estimation as MM/YYYY. [If date unknown
5	other than year, record as 01/YYYY].
Type of diabetes	Mark Type 1 or Type 2 or Other (secondary causes) or Don't know, to indicate the
71	clinical classification of diabetes.
	Please note: Female patients with a diagnosis of gestational diabetes mellitus
	(GDM) (not known to have established diabetes, i.e. a diagnosis of diabetes prior to
	pregnancy) are excluded from the Registry and should not have data collected.
Self-monitoring of glucose	Mark how blood glucose levels are self-monitored by the patient.
	If multiple, tick all that apply within the last 12 months.
	None: No regular blood glucose monitoring is performed.
	Finger pricking: A blood sample is obtained via a finger-prick and is analysed using
	testing strips and a glucometer.
	Continuous Glucose Monitoring (CGM): Subcutaneous/interstitial glucose monitoring
	systems that automatically provide the user (and/or carer) with real-time glucose
	data via a receiver or compatible phone running an application. To indicate that a
	patient uses CGM, this system should have been used for at least 1 month over the
	last 12 months.
	Flash Glucose Monitoring: A factory calibrated subcutaneous/interstitial glucose
	monitoring system that currently requires the user (and/or carer) to scan the
	attached sensor with a reader or compatible phone running an application in order
	to view recent glucose data. To indicate that a patient uses Flash Glucose
	Monitoring, this system should have been used for at least 1 month over the last 12
	months.
Finger pricking - Does the	
patient check their blood	glucose as often as recommended (Yes/No/Unsure of recommended frequency).
Finger pricking - Does the	If monitoring glucose by finger pricking, mark if the patient checks their blood

recommended?	
Finger pricking - How many	If monitoring glucose by finger pricking, indicate the number of times the patient
times a day?	does finger pricking per day on average.
If using Flash/CGM, time using sensors	If monitoring glucose using Flash/CGM, mark Yes <u>or</u> No to indicate if the patient has worn a sensor for a minimum of 14 days in the last 3 months. If Yes , mark the percentage of time the sensor was active (<70% <u>or</u> ≥70%)
Management method	If multiple, tick all that apply . DPP4 – dipeptidyl peptidase IV, GIP – glucose-
Ü	dependent insulinotropic polypeptide, GLP1 – glucagon-like peptide 1, SGLT2 – sodium-glucose cotransporter-2.
	See the Living Evidence Guidelines in Diabetes for treatment recommendations and information on each drug class. These guidelines can be found on the Australian Diabetes Society website, or with the direct links below: https://www.diabetessociety.com.au/living-evidence-guidelines-in-diabetes
Insulin duration	If the patient is on insulin, record the number of years/months the patient has been on insulin.
Insulin mode	If the patient is on insulin, mark the mode of administration(s). If multiple, tick all that apply.
	Basal: Intermediate-acting or long-acting insulin injection(s).
	Basal bolus: Insulin regime that utilises any type of basal insulin as well as any type
	of bolus insulin. Pre-mixed insulins are excluded from this category.
	Pre-mixed : Injection of any pre-mixed combination of intermediate or long-acting
	insulin with either short-acting or very short-acting insulin.
	Pump: Mode of insulin delivery being via continuous subcutaneous insulin infusion.
	If using a pump, mark the type of pump: CSII Automated or CSII Non-automated
	If using a CSII Automated pump, mark if it is a hybrid closed loop system: The
	simultaneous and integrated use of continuous glucose monitoring and an insulin
	pump with a control algorithm that may increase and decrease basal insulin delivery
	based on real-time interstitial glucose results.
Section 3. Weight & Height	
Weight	Record in kilograms the weight measurement without shoes or jacket.
	Weight may be measured in clinic or self-reported by the patient.
Height	Record in metres the height measurement without shoes.
	Height may be measured in clinic or self-reported by the patient.
Section 4. Blood Pressure	
Blood pressure	Record systolic / diastolic (mmHg) measured after 5 minutes sitting, [1st and 5th phases].
	Mark the option that describes where blood pressure was measured (In clinic/Self-reported)
Anti-hypertensive treatment	Mark Yes or No to indicate if the patient is on treatment for hypertension.
Anti-hypertensive	If Yes, select the anti-hypertensive medication(s) the patient is currently taking. ACE
medications	 angiotensin converting enzyme, ARB – angiotensin II receptor blocker. Thiazides also include thiazide-like diuretics. If on a combination tablet, tick all that apply.
Section 5. Blood Glucose Co	ntrol & Renal Function
HbA1c result	Record the most recent Haemoglobin A1c (HbA1c) result [%] in the last 12 months, or tick 'Not tested'.
	'Not tested' refers to a test which has not been ordered by the patient's
	clinician/health practitioner in the last 12 months.
HbA1c test date	If HbA1c was measured, record the date as MM/YYYY for the most recent Haemoglobin A1c (HbA1c) result in the last 12 months.
eGFR	Record the result for the most recent eGFR [mL/min per 1.73m²] in the last 12 months, or tick 'Not tested'. If the result is reported as eGFR ≥90, record as 90.

	'Not tested' refers to a test which has not been ordered by the patient's
	clinician/health practitioner in the last 12 months.
Serum creatinine	Record result measurement of serum creatinine [μ mol/L] in the last 12 months, or tick 'Not tested'.
	'Not tested' refers to a test which has not been ordered by the patient's
	clinician/health practitioner in the last 12 months.
Urinary albumin	Record amount of albumin [mg/L] or ratio. If the result is less than the lower limit of
	detection provided by the pathology service, please record the lower limit of
	detection. Example: If reported as <0.05 please record as 0.05.
	Tick 'Not tested' if a test has not been ordered by the patient's clinician/health
	practitioner in the last 12 months.
Urinary protein	Record amount of albumin [mg/L] or ratio. If the result is less than the lower limit of
	detection provided by the pathology service, please record the lower limit of
	detection. Example: If reported as <0.05 please record as 0.05.
	Tick 'Not tested' if a test has not been ordered by the patient's clinician/health
	practitioner in the last 12 months.
Section 6. Medications and Li	
Aspirin	Mark Yes or No to indicate whether the patient is on aspirin. Indicate if
	contraindicated.
Other anti-platelets	Mark Yes or No to indicate whether the patient is on any other anti-platelet
	treatment (e.g. clopidogrel, ticagrelor or prasugrel). Indicate if contraindicated.
Anti-coagulants	Mark Yes or No to indicate whether the patient is on anti-coagulants (e.g. warfarin
	or non-vitamin K antagonist oral anticoagulants (NOAC)). Indicate if contraindicated.
Lipid modifying treatment	Mark Yes or No to indicate whether the patient is on lipid lowering treatment.
	If Yes, indicate whether they are on statin, fibrate, ezetimibe, fish oil, PCSK9
	inhibitor. PCSK9 – proprotein convertase subtilisin/kexin type 9. Indicate if
	contraindicated.
	If on combination tablet, tick all that apply.
Lipids measured	Mark Yes or No to indicate if lipids have been measured in the last 12 months.
Total Cholesterol, LDL, HDL,	Record the most recent result(s) for total, LDL & HDL cholesterol and triglycerides
Triglycerides	[mmol/L] in the last 12 months or tick 'Not tested'.
<i>5</i> ,	Recorded lipids can include fasting or non-fasting results.
	'Not tested' refers to a test which has not been ordered by the patient's
	clinician/health practitioner.
Section 7. Diabetes Related E	
Mark Yes <u>or</u> No to indicate d	iagnosis/detection of diabetes related eye and foot problems in the last 12 months
AND/OR previously (prior to	the last 12 months). Answer all questions.
Retinopathy	Mark Yes or No to indicate if the ophthalmological assessment revealed any diabetic
, ,	retinopathy or maculopathy.
Treatment for retinopathy	Mark Yes or No to indicate if the patient has had any treatment for retinopathy.
. ,	Includes any of the following: laser photocoagulation treatment, intravitreal VEGF
	inhibitor injection, or vitrectomy.
Right or left cataract	Mark Yes or No to indicate if the patient currently has a cataract or has had one
5	removed.
Blindness	Mark Yes or No to indicate if the patient became legally blind (visual acuity <6/60) in
	either eye.
Peripheral neuropathy	Mark Yes or No to indicate clinical judgement following assessment using pin prick
remplieral flearopathy	and vibration (using a Biothesiometer or tuning fork) or Monofilament. Includes the
	presence of both painful and non-painful neuropathy. Also includes the presence of
	Charcot foot.
Foot ulceration	Mark Yes or No to indicate past history of foot ulceration.
Lower limb amputation	Mark Yes or No to indicate lower limb amputation.
LOWER HITTO ATTIPULATION	Amputation of toe, forefoot or leg [above or below knee], not due to trauma or
	causes other than vascular disease.
Minor/Major Lower Limb	If the patient has had an amputation in either lower limb, indicate if minor and/or
Name of American American Company of the Company of	a in the patient has had an ambutation in either lower IIMD. INGICALE II MINOF aNO/OF

Amputation	major.
	Minor = Amputation of the toe(s) or foot (below the ankle)
	Major = Amputation above the ankle.
Section 8. Other Complication	
•	agnosis/detection or event in the last 12 months AND/OR previously (prior to the last
12 months). Answer all quest	ions.
Cerebral stroke	Mark Yes or No to indicate if the patient has had a diagnosis of ischaemic stroke
	(Does not include transient ischaemic attack or haemorrhagic stroke).
Myocardial infarction	Mark Yes or No to indicate if the patient has had a myocardial infarction evidenced
	by ECG changes, plasma enzyme changes or medical documentation.
CABG/Angioplasty	Mark Yes or No to indicate if the patient has had Coronary Artery Bypass Graft
	(CABG) surgery, coronary angioplasty or stent.
Congestive cardiac failure	Mark Yes or No to indicate if the patient has symptomatic congestive cardiac failure
	with response to specific therapy.
Peripheral vascular disease	Mark Yes or No to indicate if the patient has peripheral vascular disease.
	Yes: Absence of both dorsalis pedis <u>and</u> posterior tibial pulses in either foot and/or
	symptoms of peripheral vascular disease (e.g. intermittent claudication, rest pain,
	tissue loss/gangrene) and/or Ankle-Brachial Pressure Index <0.9 and/or
	confirmatory arterial ultrasound or angiography and/or previous revascularisation
	procedure (incl. angioplasty, stent insertion or surgical bypass).
End stage kidney disease	Mark Yes or No to indicate if the patient has any of the following: stage 5 chronic
	kidney disease (eGFR <15mL/min/1.73m²) and/or dialysis-dependent (haemodialysis
	or peritoneal dialysis) and/or renal transplant recipient.
Sexual dysfunction	Mark Yes or No to indicate if the patient has/had experienced any of the following:
	If male: History or treatment of failure to achieve or maintain erection sufficient for
	satisfactory sexual intercourse. If female: History of persistent and recurrent
	problems with sexual response, desire, orgasm or pain that cause distress or
	relationship strain associated with diabetes.
Dementia	Mark Yes or No to indicate if the patient has had a formal diagnosis of dementia
	from a clinician or prescribed dementia-specific pharmacotherapy.
Depression	Mark Yes or No to indicate if the patient has had a formal diagnosis of depression
Amainta	from a clinician or prescribed pharmacotherapy for depression.
Anxiety	Mark Yes or No to indicate if the patient has had a formal diagnosis of anxiety from
N 4 a li ma a many	a clinician or prescribed pharmacotherapy for anxiety.
Malignancy	Mark Yes or No to indicate if the patient has had any type of malignancy. Exclude non-melanoma skin cancers.
Diabatic Kataacidasis (DKA)	
Diabetic Ketoacidosis (DKA)	Mark Yes or No to indicate if the patient has had any hospital admission involving
	diabetic ketoacidosis as evidenced by blood results (glucose, ketones, pH) or medical documentation.
Hyperosmolar	Mark Yes or No to indicate if the patient has had any hospital admission involving
Hyperglycaemic State (HHS)	hyperosmolar hyperglycaemic state as evidenced by blood results (glucose,
nypergrycaeriic State (nns)	osmolality) or medical documentation.
Impaired awareness of	Mark Yes or No to indicate if the patient has had any of the following:
hypoglycaemia	- Reduced ability to perceive the onset of hypoglycaemia. Includes:
Trypogrycaetilla	- Reduced symptoms of hypoglycaemia
	- Lower recognition of those symptoms, e.g. through diminished severity of
	symptoms or because those symptoms are occurring at a lower glucose level than
	previously
	- Change in symptom type, whereby the patient does not 'recognise' the new
	symptom as being related to hypoglycaemia onset
Severe hypoglycaemia	Mark Yes or No to indicate severe hypoglycaemia requiring assistance of another
	person to actively administer carbohydrates, glucagon, or other corrective actions.
Number of episodes	If Yes to 'Severe hypoglycaemia', mark the number of episodes (1-2 , 3-5 or >5).
Liver disease	Indicate severity of liver disease or if not applicable .
2.101 4.00400	Mild: cirrhosis without portal hypertension, chronic hepatitis.
	in the state of

	Moderate to severe: cirrhosis with portal hypertension.
COVID-19 positive	Mark Yes or No to indicate if the patient has tested positive to COVID-19 confirmed
	by a positive Rapid Antigen Test (RAT) or Polymerase Chain Reaction (PCR) test in
	the last 12 months AND/OR previously (prior to the last 12 months).
COVID-19 hospitalisation	If Yes to 'COVID-19', mark Yes <u>or</u> No to indicate if the patient was admitted to hospital.
	Any hospital admission, including to a general medical ward or intensive care unit (ICU).
Section 9. Mental Health Scre	
Diabetes distress	
Diabetes distress	Mark Yes or No to indicate if the patient has been screened for diabetes distress
	using a validated questionnaire/measure in the last 12 months.
	Example: Problem Areas In Diabetes questionnaire (PAID) screening tool,
	Diabetes Distress Scale (DDS).
Depression	Mark Yes or No to indicate if the patient has been screened for depression using a
	validated questionnaire/measure in the last 12 months.
	Example: Patient Health Questionnaire (PHQ-9) screening tool.
	This only applies to patients who have NOT had a formal diagnosis of depression
	from a clinician or prescribed pharmacotherapy for depression in the last 12 months.
Anxiety	Mark Yes or No to indicate if the patient has been screened for anxiety using a
	validated questionnaire/measure in the last 12 months.
	Example: Generalized Anxiety Disorder scale (GAD- 7) screening tool.
	This only applies to patients who have NOT had a formal diagnosis of anxiety from a
	clinician or prescribed pharmacotherapy for anxiety in the last 12 months.
	PATIENT HEALTH & WELL-BEING QUESTIONNAIRE
Section 1. Smoking & Vaccina	
Currently smoke tobacco	Mark if the patient currently smokes <u>any tobacco material</u> (Yes/No).
Currently smoke tobacco	[i.e. cigarettes/cigars/e-cigarettes(vaping)]
Previously smoked tobacco	If No to 'Currently smoke tobacco', mark if the patient previously smoked any
	tobacco material (Yes/No).
COVID-19 vaccination	Mark if the patient had a COVID-19 vaccination in the last 6 months (Yes/No).
Flu/Influenza vaccination	Mark if the patient had a flu (influenza) vaccination in the last 12 months (Yes/No).
Pneumococcal vaccination	Mark if the patient is up-to-date with their pneumococcal vaccination
	(Yes/No/Unsure).
Section 2. Health Professional	
Endocrinologist	Mark if the patient attended an Endocrinologist in the last 12 months (Yes/No).
Diabetes Educator/Nurse	Mark if the patient attended a Diabetes Educator/Nurse Practitioner in the last 12
Practitioner	months (Yes/No).
Dietitian	Mark if the patient attended a Dietician in the last 12 months (Yes/No).
Podiatrist	Mark if the patient attended a Podiatrist in the last 12 months (Yes/No).
	· · · · · · · · · · · · · · · · · · ·
Ophthalmologist	Mark if the patient attended an Ophthalmologist in the last 12 months (Yes/No).
Optometrist	Mark if the patient attended an Optometrist in the last 12 months (Yes/No).
Psychologist/Psychiatrist	Mark if the patient attended a Psychologist/Psychiatrist in the last 12 months (Yes/No).
Social Worker	Mark if the patient attended a Social Worker in the last 12 months (Yes/No).
Dentist	Mark if the patient attended a Dentist in the last 12 months (Yes/No).
Exercise Physiologist/	Mark if the patient attended an Exercise Physiologist/Physiotherapist in the last 12
Physiotherapist	months (Yes/No).
Ambulance	Mark if the patient needed an Ambulance for their diabetes in the last 12 months (Yes/No).
	ı

Emergency Department	Mark if the patient attended an Emergency Department for their diabetes in the last
	12 months (Yes/No).
Section 3. Medication Use	
Medication use practices	Mark if the patient has not taken their medications as recommended in the last 2 weeks (Yes/No). If Yes, indicate the number of times.
Section 4. Foot care	
Feet Checked	Mark if the patient has had their feet checked by a professional (e.g. doctor, nurse, podiatrist) in the last 12 months (Yes/No).
Self-check of feet	Mark the option that best describes how often the patient self-checks their feet (Daily, Weekly, Monthly, Rarely/never).
Section 5. Nutrition/Diet Man	agement
Do you know what foods are best to eat?	Mark if the patient has enough knowledge about what foods and how much are best to eat (Yes/No).
Do you have enough time to prepare healthy meals?	Mark if the patient has enough time to prepare healthy meals (Yes/No).
Does it cost too much to eat healthy meals?	Mark if the patient feels it costs too much to eat healthy meals (Yes/No).
If you have Type 1 diabetes, do you find it hard to count carbs/weigh food?	If the patient has type 1 diabetes, mark if the patient finds it hard to count carbs and/or weigh food (Yes/No).
Section 6. Physical Activity	
Physical activity	Mark the usual weekly duration of time (150 mins/week or more, less than 150 mins/week, or rarely/never) spent performing moderate or vigorous intensity physical activity. Physical activity is calculated in 'total minutes per week' by summing the total minutes of walking, moderate and/or vigorous physical activity in a usual 7-day period. Vigorous physical activity is weighted by a factor of two to account for its greater intensity. Intensity of physical activity is defined by The National Physical Activity Guidelines for Australians: Moderate physical activity causes a slight but noticeable increase in breathing and heart rate, the person can comfortably talk but not sing. Vigorous physical activity causes the person to 'huff and puff,' talking in full sentences between breaths is difficult.
Muscle strengthening	Mark whether the patient does any muscle strengthening exercise in a usual week.
exercise	(Yes/No). Muscle strengthening activities are physical activities that maintain or improve the strength, power, endurance and size of skeletal muscles. This can be physical activity with free weights, body weight or resistance machines/bands, or house/garden activities that involve muscular effort, such as, lifting, carrying or digging.